Optimisation and comparison of a phenotypic maldi-tof assay with molecular and phenotypic methods for the rapid identification of selected fungal, nocardia and nontuberculous mycobacteria. by Immelman, Wilma
OPTIMISATION AND COMPARISON OF A PHENOTYPIC MALDI-TOF 
ASSAY WITH MOLECULAR  AND PHENOTYPIC METHODS FOR THE 
RAPID IDENTIFICATION OF SELECTED FUNGAL, NOCARDIA AND 
NONTUBERCULOUS MYCOBACTERIA.  
Wilma Immelman 
Thesis presented in partial fulfilment of the requirements for the degree of Masters of 
Medical Microbiology in the Faculty of Medicine and Health Sciences at the University of 
Stellenbosch 
Supervisor: Dr KGP Hoek 
Co-supervisor: Dr Wasserman 
March 2020 
DECLARATION 
By submitting this thesis electronically, I declare that the entirety of the work contained 
therein is my own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University will 
not infringe any third party rights and that I have not previously in its entirety or in part 
submitted it for obtaining any qualification. 
Date: March 2020





Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has 
been utilised in clinical microbiology laboratories for several years, but is mostly used for the rapid 
and accurate identification of bacteria and yeasts; and to a lesser extent for nontuberculous 
mycobacteria (NTM), Nocardia and moulds. 
Due to the variety of methods used for the identification of NTM, Nocardia and moulds , the promise 
of an identification method ‘fit for all’, as reported in some studies, would have a significant impact 
on the work flow in a diagnostic laboratory. The MALDI-TOF MS is a relatively low-cost technology 
with a quick turnaround time following culture. Promising results were reported in various studies 
and includes identification rates of 87.7% - 99.0% for NTM, 76.0% - 98.0% for Nocardia and 66.8% 
- 94.0% for moulds.
The aim of this study was to compare the identification of selected NTM, Nocardia and moulds using 
MALDI-TOF MS with various phenotypic and molecular methods including routine fungal culture, the 
Genotype Mycobacterium CM /  AS assays, as well as a pan-bacterial and pan-fungal sequencing 
approach. The study also included a cost and workflow analysis between the different methods 
employed.  
Our study produced identification rates of 21.8% for NTM, 62.5% for Nocardia and 38.5% for moulds. 
A recurring theme for all organism identifications on the Vitek MS was a high rate of “no 
identifications”, despite adequate protein spectral profiles being generated as well as the majority of 
the organisms being represented in the Vitek MS Knowledge Base Database. Despite significant 
troubleshooting of the methodology for all organisms, the percentage of successful identifications 
did not improve. The manufacturer representatives were unable to resolve the issues during the 
course of this study, suggesting that there may be a software or hardware related problem. 
Based on the Vitek MS instrument shortcomings and cost and workflow analysis, we recommend 
the Mycobacterium CM/AS kit for the speciation of NTMs and the phenotypic identification of moulds. 
ITS Pan-Fungal sequencing should be used where turnaround time is critical or where culture 
negative disease is suspected. While the Vitek MS showed promise for Nocardia identification, the 
cost thereof given the large kit size and short stability, makes cost prohibitive. Similarly MLSA 
analysis provided the most identifications to the species level, but is cost prohibitive. While 16S rRNA 
sequencing mostly only reported Nocardia to the genus level, it remains the only feasible option for 





In summary, the Vitek MS requires regular fine-tuning and technical intervention and support. The 
instrument is perhaps not suited to a high throughput laboratory for the identification of NTMs, 


































MALDI-TOF MS is al vir jare in gebruik in die kliniese mikrobiologie laboratoriums, maar meestal vir 
die identifikasie van gis en bakterieë; en tot n mindere mate vir die identifikasie van nie tuberkulose 
Mikobakterieë (NTM), Nocardia en skimmel.  
 
As gevolg van verskeie metodes beskikbaar vir die identifikasie van NTM, Nocardia  en skimmel, die 
belofte van n metode wat geskik is vir al die bogenoemde organismes soos gerapporteer deur 
verskeie studies, sal 'n beduidende invloed hê op die werksvloei in 'n diagnostiese laboratorium. Die 
MALDI-TOF MS is 'n relatiewe laekoste-tegnologie met 'n vinnige omkeertyd. Beloofde resultate is 
in verskillende studies aangemeld en rapporteer identifikasies van 87,7% - 99.0% vir NTM, 76.0% - 
98.0% vir Nocardia en 66.8% - 94.0% vir skimmels.  
 
 
Die doel van die studie was om die identifkasie van geselekteerde NTM, skimmel en Nocardia isolate 
op die MALDI-TOF-MS te vergelyk met verskeie fenotipiese en molekulêre metodes wat insluit die 
Genotype Mycobacterium CM / AS metodes, asook pan-bakteriële en pan-skimmel DNA volgorde 
benadering. Die studie sluit ook in n koste en werksvloei analise tussen die verskeie metodes. 
 
Ons studie het identifikasies van 21.8% vir NTM, 62.5% vir Nocardia en 38.5% vir skimmel 
geproduseer. 'n Herhalende tema vir alle organisme-identifikasies op die Vitek MS was 'n hoë mate 
van "geen identifikasies", ondanks die feit dat voldoende proteïen-spektrale profiele gegenereer is, 
sowel as die meerderheid van die organismes was verteenworrdig in die Vitek MS databasis. 
Ondanks beduidende probleemoplossing van die metodologie vir alle organismes, het die 
persentasie suksesvolle identifikasies nie verbeter nie. Die vervaardiger se verteenwoordigers kon 
nie die probleme gedurende hierdie studie oplos nie, wat daarop dui dat daar 'n sagteware- of 
hardeware verwante probleem kan wees.  
 
Op grond van die Vitek MS-instrument tekortkominge en koste- en werkvloei-analise, beveel ons die 
Mycobacterium CM / AS aan vir die spesifikasie van NTM's en die fenotipiese identifikasie van 
skimmel. Pan-Fungal-opeenvolging moet gebruik word waar die omkeertyd van kritieke belang is of 
waar kultuur negatiewe siektes vermoed word. Terwyl die Vitek MS 'n belofte getoon het vir Nocardia 
identifikasie, maak die koste daarvan, gegewe die groot stelgrootte en kort stabiliteit, die metode nie 
koste-effektief nie. Op dieselfde manier het die MLSA-analise die meeste identifikasies op die 
spesievlak verskaf, maar dit is nie koste effektief nie. Terwyl 16S rRNA-volgorde meestal slegs 
Nocardia op die genusvlak gerapporteer is, bly dit die enigste haalbare opsie vir bevestiging van 





Samevattend benodig die Vitek MS gereelde fyninstellings en tegniese ingryping en ondersteuning. 
Die instrument is miskien nie geskik vir 'n laboratorium met 'n hoë deurvloei vir die identifisering van 
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 GENERAL INTRODUCTION 
 
Matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF MS) has been widely 
implemented in clinical microbiology laboratories for the identification of bacteria and yeasts. The 
use of this methodology for the rapid identification of nontuberculous mycobacteria (NTMs), Nocardia 
and moulds has been reported, but to a lesser extent. Here we provide a review of the most common 
laboratory diagnostic techniques to speciate NTMs, Nocardia and moulds, as well as discuss the 
potential of MALDI-TOF MS as a diagnostic tool in the routine laboratory.  
1.1 Nontuberculous Mycobacteria 
1.1.1 Background 
The genus Mycobacterium  consists of more than 190 species that live in a wide variety of natural 
environments and are organisms that are responsible for human diseases such as tuberculosis (TB), 
leprosy, Buruli ulcer, as well as pulmonary nontuberculous disease. While some members of the 
Mycobacterium spp. group are responsible for clinical disease, others are environmental organisms 
that can be present as commensals or isolated in the laboratory as environmental contaminants (1–
3). 
 
Mycobacteria are classified into 2 main groups according to their differences in epidemiology and 
association with disease: (a) Mycobacterium tuberculosis complex (MTC), and (b) NTMs. M. leprae 
and M. ulcerans cause distinct diseases, leprosy and Buruli ulcer respectively, and are therefore not 
included in the category of NTM (4). 
 
While M. tuberculosis remains the most clinically significant organism in the genus, there is a steady 
increase in the number of infections caused by NTMs due to the increase in  the number of 
immunocompromised individuals (5,6).  
 
1.1.2 The pathogen: Nontuberculous Mycobacteria 
NTM are important opportunistic pathogens that can be found in an abundance in the environment 
of which water and soil are natural reservoirs. These organisms have also been isolated from animal, 
milk and food products. Opportunistic infections caused by NTMs have a tremendous impact on 
people that are immunocompromised and cause life-threatening infections in acquired 
immunodeficiency syndrome (AIDS) and transplant patients (7). Transmission of NTMs does not 
occur from person-to-person and infection is acquired from the environment (8). NTMs have been 





associated infections. Biofilm formation is the organism’s survival response to radical changes in the 
environment which provides protection against external stressors such as disinfectants and 
antibiotics (7,9). Organisms residing in biofilms may therefore be more resistant to disinfectants and 
antibiotics. 
 
Unlike TB, NTM infections is not a notifiable disease (in South Africa), which results in less accurate 
knowledge of the exact impact NTM infections have on public health (7). However, we do know that 
the rate of NTM infections is increasing due to the increased number of immunocompromised 
patients (10).  
 
Over the recent years, the apparent rise of NTM infections and the increased number of recognised 
novel species may also be due to the availability of advanced genotypic molecular techniques (10). 
Since 2011, 37 novel species or subspecies have been recognised and a full list is available at 
http://bacterio.net/mycobacterium.html (last updated in 2017).  A select number of the most common 
and clinically relevant NTMs are discussed below. 
 
NTMs are classified according to the rate of their growth and are divided into  slow  or fast growers. 
Fast growing NTMs produce mature colonies on solid medium under ideal conditions in ≤ 7 days, 
whereas slow growing NTMs require more than 7 days (4,11). Examples (not limited to) of slow 
growing NTMs include the M. avium complex (MAC), M. kansasii, M. xenopi and M. simiae. Rapid 
growers include M. abscessus, M. fortuitum, M. smegmatis and M. chelonae (8,9). 
 
One of the most common NTM species identified in our setting is M. avium complex (MAC) 
comprising of two species, M. avium and M. intracellulare. M. avium consists of four subspecies: M. 
avium subsp. avium, M. avium subsp. hominissuis, M. avium subsp. paratuberculosis, and M. avium 
subsp. silvaticum (4). 
MAC are slow growing Mycobacteria and most commonly isolated from respiratory specimens as 
they cause pulmonary infections in immunocompetent and immunocompromised individuals. 
Disseminated disease in immunocompromised patients, especially patients living with HIV/AIDS, 
may occur (12). In addition to pulmonary infections, M. avium can infect the lymph nodes, bones, 
joints, skin and soft tissue and can spread systemically (13). M. intracellulare is primarily a respiratory 
pathogen and is not a common cause of disseminated disease (4).  
The identification of species within the MAC group is crucial to distinguish between chronic 
pulmonary infection and transient colonisation by different species within this group (4,11,14), as 
members of the MAC group differ in virulence and ecology. The accurate differentiation between the 







The second most frequently NTM pathogen isolated from clinical samples is M. abscessus complex  
and it represents more than 80.0% of the rapid growing NTMs identified (4).  M. abscessus complex 
consists of three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. bolletii, and M. 
abscessus subsp. massiliense. This complex of mycobacteria is mostly environmental and occurs 
in soil, water and dust. It is often isolated from respiratory samples taken from patients with cystic 
fibrosis. In addition to causing pulmonary disease, this group of organisms is also responsible for 
skin, soft tissue and bone infections (4,11). The differentiation between the subspecies is crucial to 
optimise treatment as they differ in response to chemotherapeutic agents (16).  
 
Another common fast growing NTM complex is the M. fortuitum complex  which consists of the 
following species: M. fortuitum, M. peregrinum, M. senegalense, M. setense, M. septicum, M. 
porcinum, M. houstonense, M. boenickei, M. brisbanense and M. neworleansense. Similar to M. 
abscessus complex, this group of organisms can also cause skin, soft tissue and bone disease, but 
rarely causes pulmonary disease. 
 
Another common NTM isolated in the laboratory is M. kansasii, a slow grower, which, if isolated from 
human specimens, is almost always associated with disease. M. kansasii is commonly isolated from 
municipal water, which can be a reservoir for infection with this organism (4). Infection with M. 
kansasii resembles pulmonary infection with M. tuberculosis in that it involves cavitary infiltrates in 
the upper lobes, but rarely disseminates from the lungs, except in immunocompromised patients. 
Risk factors for infection include chronic obstructive pulmonary disease (COPD), pneumoconiosis, 
cancer, alcoholism and HIV/AIDS (4,17). 
 
1.1.3 Laboratory identification methods 
It is of critical importance to accurately identify NTM infections  so as to establish the clinical 
relevance of the organism and to assist the clinician in selecting the appropriate treatment options 
and patient management, avoiding drug over exposure and toxicity (18,19).   
For decades, identification and speciation of NTMs relied on multiple biochemical tests and the 
phenotypic traits of the organism, which includes determination of a pigment with or without exposure 
to light, growth rate and colony morphology (18,20). Biochemical identification methods (e.g. the 
niacin accumulation test, nitrate reduction assay and catalase test) are however unable to correctly 
identify new emerging species (20).  
 
High-performance liquid chromatography (HPLC) has been used to provide a more specific 
identification and to better discriminate between species, but this method is not suitable for a clinical 





available (21). In addition, HPLC requires pure cultures grown on solid media, which delays the 
turnaround time (19). 
 
The growth of Mycobacterium spp. on solid media (e.g. LJ) is regarded as the gold standard and is 
often used as the reference method for the validation or verification  of new diagnostic tests (22). 
However there has been a move to liquid based culture such as the automated BACTEC 
Mycobacterial Growth Incubator Tube (MGIT) (Beckton Dickenson, United States) method. While 
the MGIT liquid culture system has a higher sensitivity and negative predictive value than LJ solid 
media, the latter has been shown to have better specificity and positive predictive values (22,23). 
Liquid culture also has a significantly shorter time to positivity than that of solid culture methods (23). 
 
Speciation  of Mycobacterium tuberculosis complex (MTC) directly from clinical samples can be 
achieved by identification methods such as GeneXpert MTB/RIF (Cepheid, United States) and 
Genotype MTBDRplus (Hain Lifesciences, Germany) assays, but the identification of NTMs still 
currently requires a positive culture as there are currently no commercially available NTM 
identification methods which can be run directly from clinical samples (24). . 
 
PCR based assays allow for the speciation of mycobacterial isolates. DNA sequencing is considered 
the gold standard (1). Several targets have been shown to be suitable for mycobacterial identification 
and include the 16S and 23S rRNA genes, the RNA polymerase beta subunit (rpoB), secA (Protein 
translocase subunit) and the 65-kDa heat shock protein (hsp65) genes (1,18,25). Sequencing is 
labour intensive, technically complex and clinical laboratories do not have the resources or specific 
equipment and expertise to routinely perform these tests (1,25). 
 
More prevalent methods for NTM speciation includes PCR hybridisation-based methods such as the 
GenoType Mycobacterium CM / AS assays (Hain Lifescience, Germany) which detects 14 of the 
most common mycobacterial species (CM) and 17 of the less common mycobacterial species (AS) 
by targeting the 23S rDNA region (21) of all mycobacterial species.   
Both GenoType Mycobacterium assays utilise DNA Strip technology (Figure 1-1): The procedure 
consists of three basic steps: (a) Extraction of DNA from the cultured media, (b) multiplex 
amplification with biotinylated primers, and (c) reverse hybridisation. After chemical denaturation of 
the amplification products, the single-stranded amplicons bind to the membrane which is coated with 
complementary nucleic acids in a process called hybridisation. The combination of buffer 
composition and a particular temperature ensures the highly specific binding of complementary DNA 
strands. The sequences of the bacterial species are differentiated by the probes. Alkaline 
phosphatase is conjugated with streptavidin and binds via the streptavidin moiety to the amplicons’ 





coloured precipitate on the membrane strips. A banding pattern is obtained which is easily 




Figure 1-1 Overview of the GenoType Mycobacterium CM / AS Assays technology (Hain-lifescience, 
Germany) 
 
The speciation of potential pathogens in a clinical laboratory requires identification methods that are 
rapid, reliable and cost effective. Accurate diagnosis of the etiological agent has a direct impact on 
patient treatment as the appropriate antimicrobial therapy can be administered earlier (26). MALDI-
TOF is a rapid and cost effective system that can be implemented in a clinical laboratory for the 




Nocardiosis is a rare opportunistic disease that affects humans as well as animals (27,28). Nocardia 
is a saprophytic environmental organism that occurs in soil, water, dust, air and decaying organic 
matter (28,29). Nocardia belong to the actinomycetes group (Phylum: Actinobacteria, Order: 
Actinomycetales) of bacteria which are aerobic, non-spore forming, non-capsulated, branching 
filamentous Gram-positive bacilli which are weakly acid-fast (28,30). 
 
The organism was discovered by Edmond Nocard in 1888 in cattle on an island of West Indies and 
was thought to be the cause of bovine farcy (28,31). It was first described as a fungus (28) but was 
reclassified as an aerobic bacterium under the genus Nocardia in 1889 (32) and was named 
Nocardia farcinica. A further 5 other species were classified under the genus Nocardia  by Trevison 
(31). The first clinical case of human disease caused by this organism was reported in 1890 in a 52-
year old glass blower (28). 
 
Nocardia is not part of normal flora but can colonise the airways and is rarely a laboratory 
contaminant. If this organism is isolated in the laboratory it should be evaluated as a potential 





laboratory to ensure the necessary steps are taken for the isolation and identification of the causative 
organism (30). 
 
Nocardia is regarded as an opportunistic pathogen, and most recorded cases are from the 
immunocompromised patient population in which it can be life-threatening (28). Immunocompetent  
individuals can also be infected (32), but are less likely to experience dissemination than their 
immunocompromised counterparts, which are more likely to develop bloodstream infections, require 
hospitalisation and experience a higher mortality due to Nocardia infections (33). Comorbidities 
which increase the risk of Nocardia infection include HIV/AIDS, transplant patients, tuberculosis, 
alcohol abuse, diabetes mellitus, cirrhosis, neoplastic disease, corticosteroid therapy, connective 
tissue and lung disorders (28,30,32). Timeous laboratory diagnosis of Nocardia infections is 
important as there are many other clinical conditions that it can mimic (i.e. the clinicians may not 
suspect Nocardia until the laboratory informs them of the culture result), and a delay may result in 
inappropriate therapy, which can lead to treatment failure and a poor prognosis (30). 
 
There are 92 recognised Nocardia spp. that are listed in the “List of Prokaryotic names with Standing 
Literature” (http://www.bacterio.net/index.html) of which 54 species are considered clinically 
significant (31). These include N. abscessus, N. nova complex, N. transvalensis complex, N. 
farcinica, N. cyriacigeorgica, N. brasiliensis, N. pseudobrasiliensis and N. otitidiscaviarum (34). In 
the past N. asteroides was considered to be the most commonly isolated Nocardia spp. involved in 
human disease (28,31). The susceptibility patterns between isolates of N. asteroides differs 
significantly and this gave rise to the grouping of the N. asteroides complex into 6 groups depending 
on their antimicrobial susceptibility pattern: N. abscessus , N. brevicatena / N. paucivorans , N. nova 
complex , N. transvalensis complex , N. farcinica , and N. cyriacigeorgica . These organisms can not 
be speciated by phenotypic means, but with the evolution of molecular techniques, including 
sequence analysis, it is now possible to discriminate between these species and the term N. 
asteroides complex is no longer used. As these species can now be differentiated from each other, 
N. asteroides is now rarely identified from clinical samples and is not the most commonly isolated 
Nocardia spp. anymore (31). 
1.2.2 Nocardiosis 
Nocardiosis can present as an acute, subacute or more frequently chronic disease (27,29), involving 
the skin, lungs and central nervous system (32). The respiratory tract is the main portal of entry (32) 
and can result in asymptomatic colonisation or progression to the most common manifestation of 






Common signs and symptoms of pulmonary nocardiosis may vary but include fever, cough, weight 
loss, pleural pain, dyspnea and anorexia  (28,36). These symptoms  are non-specific (28) and cannot 
be distinguished from patients with pulmonary infections caused by other microbial agents (29). The 
signs and symptoms may be confused with those of chronic lung infections such as fungal or TB 
infections (36,37), which consequently may lead to incorrect treatment of the patient with anti-
tuberculous drugs (37). 
 
Other clinical manifestations include corneal ulcers, mycetoma and encephalitis (28). Cutaneous 
nocardiosis in humans results from contact with the bacteria through trauma like cuts or scrapings 
on the skin, which can result in cellulitis or ulcers (30). There is no evidence of human to human 
transmission and isolation of these patients is not recommended (27,30). 
 
The prognosis is variable depending on the site and extent of infection and the underlying host 
factors. The majority of patients (Almost 100.0%) with skin and soft-tissue infections and 90.0% of 
pulmonary infections can be cured with the appropriate therapy (29). Disseminated nocardiosis can 
be cured in 63.0% of patients but only 50.0% of patients with brain abscesses will be cured with 
therapy (29).   
 
Different Nocardia spp. vary in their ability to cause infection in humans and in their response to 
antimicrobial therapy. It is therefore  critical to differentiate between the different species as it can 
have a direct impact on patient treatment and provides important information for epidemiological 
purposes (37,38). Prolonged treatments of 6 to 12 months are recommended in patients with a 
severe immunocompromised immune system (32). 
1.2.3 Laboratory identification methods 
The first step in diagnosing Nocardia infection is the microscopic examination and culture of the 
organism from specimens originating from the site of infection (29,30). The Gram stain and a 
modified acid-fast stain (Ziehl-Neelsen) is important as it can guide the clinician while waiting for the 
culture results (27).  
 
Microscopically Nocardia spp. can be distinguished from Mycobacterium as their morphology differs 
and Mycobacterium do not stain well with Gram or modified acid-fast stains. While Actinomyces may 
have a similar morhpology to Nocardia, it is modified acid-fast stain negative. Non-selective media 
used in the laboratory for the culture of bacteria, fungi and Mycobacteria is suitable for the isolation 
of Nocardia spp. (27). Growth of Nocardia colonies can appear after 48 hours but is usually present 
within 3-5 days (29,30). Some species may require growth for up to 3 weeks (27). Plates for routine 





therefore easily be missed from clinical samples. Therefore, if there is a clinical suspicion of 
nocardiosis, it is advised to inform the laboratory to prolong incubation of the culture plates (30). 
However, in samples were mixed flora are present, like sputum, the faster growing bacteria can 
easily overgrow the Nocardia spp. and it may be missed (27). 
 
If growth is successful , species identification can be achieved by biochemical reactions including 
hydrolysis of adenine, casein, tyrosine, xanthine, and hypoxanthine (27,39) but these are laborious, 
time-consuming methods (35) which increase turnaround time and are less definitive (37). 
Furthermore, biochemical methods are insufficient to accurately distinguish between the clinically 
relevant species (31). 
 
Molecular methods targeting specific Nocardia gene regions have been employed for accurate 
identification of Nocardia spp. (40). 16S rRNA sequence analysis was considered the gold standard 
for definitive Nocardia spp. identification (38,40–43). A hypervariable region near the 5’ terminus of 
the 16S rRNA gene exists in all Nocardia spp. and this allows for the application of a partial (500 bp) 
16S rRNA sequence for the differentiation between the majority of clinically recognised Nocardia 
spp. However, there have been reports that the multiple copies of the 16S rRNA gene in certain 
Nocardia spp. may differ slightly with regards to sequence content (44). This  may lead to 
misidentifications, such as in the case of N. nova (38,40,44,45). 16S rRNA sequence analysis can 
theoretically detect Nocardia directly from clinical samples, however, to save costs, the majority of 
samples are first sent for routine Microbiological, Culture and Sensitivity (MCS) investigations and it 
is then prefferential to do PCR from the positive culture which would have a higher bacterial load. 
 
Due to the complexities associated with 16S rRNA gene sequencing, multilocus sequence analysis 
(MLSA) using 16S rRNA, rpoB (β-subunit of DNA-dependent RNA polymerase), erm (erythromycin 
ribosomal methylase), hsp65 (65-kDa heat shock protein), gyrB (β-subunit of the type II DNA 
topoisomerase) and/or secA1 (SecA preprotein translocase) genes has been proposed as an 
alternative method able to identify known as well as novel species (37,38,45). The genus Nocardia 
exhibits genetic diversity and MLSA using multiple housekeeping genes can be used for 
phylogenetic analysis in that sequence clusters represent species clusters (43). In this genus there 
are distinct species that are closely related based on their gene sequences similarities. An example 
of such a group is the N. abscessus complex which includes N. abscessus, N. arthritidis, N. asiatica 
and N. beijingensis.  
Sequencing methods such as 16S rRNA and MLSA are expensive and time consuming, and are not 
available in many routine clinical laboratories. Isolates must often be referred to a reference 








Mycology is a specialised discipline involving the study of fungi which includes their taxonomy, 
genetic and biochemical properties as well as the impact they have on the environment. In the past 
fungi were not regarded as clinically significant, but today a number of species found in the 
environment are regarded as important causes of human disease (47), particularly in 
immunocompromised patients. Fungi are widely distributed on Earth, of which many are free-living 
in soil, water, air, food and clothing; while others form parasitic or symbiotic relationships with plants 
or animals (48). Fungi are important to many household and industrial processes such as the 
production of wine, beer, bread and certain cheeses. It is also considered as a source of food  (e.g. 
mushrooms, morels and truffles) and drugs (e.g. penicillin antibiotic) (49).  
 
In the past two decades there has been an substantial increase in the severity and incidence of 
opportunistic invasive fungal infections (50). This is once again due to an increase in 
immunocompromised patients due to transplants, corticosteroid use and HIV/AIDS (51). The 
alterations in the host caused by immunosuppressive agents and/or serious disease may lead to 
infections by organisms that are normally considered to be non-pathogenic normal flora . Aspergillus 
is one such mould that can cause opportunistic disease (47). The spores of Aspergillus are abundant 
in the environment (including soil and food) and it is usually considered to be a contaminant (52). 
Other risk factors include surgical procedures and antibacterial therapy (47). 
 
There are over 200 000 species of fungi but only 100 to 150 of them are considered to be human 
pathogens. Of these, 25 species account for the majority of human infections. These organisms are 
mostly saprophytic environmental organisms, living on dead or decaying organic matter. Humans 
are generally very resistant to fungal infections, except those caused by dimorphic fungi, and 
become infected by inhaling the spores or due to inoculation during tissue trauma. The capability of 
these organisms to cause serious disease in immunocompromised individuals means that the 
laboratory identification procedures must allow for the identification and reporting of a wide range of 































Figure 1-2 Classification of moulds 
Adapted from (53,54) 
 
An alternate, but less popular, clinical classification system exists where fungi are grouped according 
to the type of mycoses (infections caused by moulds) they are involved in, i.e.  superficial 
(cutaneous), subcutaneous, systemic or opportunistic mycoses (47). 
 
1.3.2  Infections caused by moulds 
 Mycoses 
• Superficial (cutaneous) mycoses 
Superficial (cutaneous) mycoses refers to fungal infections of the skin, hair and nails without direct 
invasion of the deeper tissues (53). This infection is classified according to the site of disease and 
includes tinea capitis (head), tinea corporis (body), tinea cruris, tinea pedis and tinea barbae. 
Onychomycosis refers to the infection of nails by a nondermatophyte fungi, although the term is 
widely used for infection of the nail by any fungal agent. They are seen worldwide and affect 
approximately 20.0% - 25.0% of the world’s population (55). Superficial mycoses also  include 























responsible for the majority of superficial mycoses (47). This group  consists of three genera: 
Trichophyton, Microsporum and Epidermophyton (53).  
 
• Subcutaeous mycoses 
Subcutaneous mycoses include chromoblastomycosis, mycetoma, and phaeohyphomycotic cysts. 
These fungal infections do not disseminate to distant sites but remain in the subcutaneous tissue 
(47).  
• Systemic mycoses 
Systemic fungal infections usually involve the lungs and can disseminate extensively and involve 
any organ system. Fungal genera usually involves in systemic mycoses involve Blastomyces, 
Coccidioides, Histoplasma and Paracoccidioides (47). 
 
  Aspergillus 
Aspergillosis is a disease that presents with a variety of clinical manifestations which may include 
the presence of a fungus ball in the lung or sinus (aspergilloma), asthma, allergic bronchopulmonary 
aspergillosis, keratitis, chronic pulmonary aspergillosis and otomycosis. Invasive disease is rare, and 
occurs only in severely immune compromised patients. Of the Aspergillus taxon, the species that is 
most commonly implicated  in human disease is A. fumigatus followed by A. flavus (52). 
 
  Other moulds 
The mucormycetes, hyalohyphomycetes and phaeohyphomycetes are groups of fungi that represent 
the non-Aspergillus filamentous fungi. The most prevalent cause of non-Aspergillus mould infections 
in humans is due to the mucormycetes of which Rhizopus is the most common, followed by Mucor, 
Rhizomucor and Lichtheimia. The hyalohyphomycetes (hyaline moulds) are fungi with branching 
septate hyphae but lack pigmentation. Microscopically it is very difficult to differentiate 
hyalohyphomycetes from Aspergillus. The most prevalent genera in this group of fungi are Fusarium 
and Scedosporium followed by the less frequently detected fungi such as Paecilomyces, 
Acremonium, Schizophyllum and Rasamsonia (56). The phaeohyphomycetes are also called the 
dematiaceous fungi due to the dark pigmentation of the colonies which is a result of melanin 
production. Genera included in this group of fungi include Alternaria spp., Bipolaris spp., Wangiella 
spp., Madurella spp., Fonsecaea spp., Cladophialophora spp., Curvularia spp., Exophiala spp. and 






1.3.3 Laboratory identification methods 
Diagnosing invasive fungal disease is complicated by the lack of sensitivity and specificity of current 
laboratory identification methods. Often the result is not obtained in an appropriate turnaround time 
to make the diagnosis clinically useful. Rapid, accurate species level identification is crucial to 
identify clinically important isolates for the timely onset of anti-fungal treatment – a critical contributor 
to patient outcome (50,53,58,59). 
 
For many years the gold standard for diagnosing fungal infections was the culture of the clinical 
sample which included microscopy and histopathology (50). Identification of filamentous fungi by 
these methods is reliant on the observation of reproductive structures, which can be subjective (51) 
and requires highly trained personnel (60). Growth from clinical specimens takes about 3 weeks and 
once the culture is positive it may take days before an identification can be made (50). This results 
in a prolonged turnaround time due to extended incubation periods (60). A contributing factor to the 
extended turnaround time is the identification of unusual or problematic fungi which are usually 
referred to a reference laboratory for speciation by molecular methods such as DNA sequencing 
(61). Molecular methods for the identification of filamentous fungi allows the differentiation of several 
closely related species which are morphologically identical (51), for  example A. lentulus which is 
morphologically identified  as A. fumigatus. Differentiation of this species impacts patient treatment 
(62). 
 
DNA sequencing methods   are highly accurate, but they are expensive and it may take two to three 
days before the identification results is available (51,59). However they can be performed directly 
from the clinical sample and are not culture dependent. DNA sequencing is usually confined to 
reference laboratories and is not widely available in the clinical laboratory setting, which may 
contribute to an increased turnaround time (51).  
 
The ITS (internal transcribed spacer) region is the most commonly sequenced DNA target for fungal 
identification and speciation (63,64). The ITS regions are ideal targets for identification of fungal 
organisms due to their location between the conserved 18S, 5.8S and 28S rRNA gene sequences 
(64). The ITS regions of the gene are very stable, conserved within species and occur in multi-copies. 
The latter increases the sensitivity of the assay as compared to targeting single copy regions (65). 
The target section is located between the 18S of the small subunit (SSU) and the large subunit 28S 
(LSU) of the ribosome (64). While most fungal species have been identified by targeting the ITS 
region, some difficulties have been experienced with the identification of Alternaria, Aspergillus, 







A future concern  is the loss of well-trained, experienced mycology laboratory technologists due to 
retirement or resignation, resulting in replacement by less experienced staff (47). The spectrum of 
fungal pathogens identified in the clinical laboratory has undergone major expansion in the last 30 
years due to the increase of immunocompromised patients. These patients are susceptible to 
opportunistic fungal pathogens previously rarely encountered and the identification of these 
organisms in the laboratory may be a challenging task even for the most qualified, experienced 
mycologist (50). 
 
The need for an affordable, rapid and accurate method for the identification of fungi to the species 
level exists, as traditional phenotypic identification methods are time-consuming, lack adequate 
accuracy, and molecular methods are not readily available in the majority of clinical laboratories (51). 
The application of MALDI-TOF MS for the routine identification of fungi is a promising method which 
may fulfil these requirements (66).  
 
1.4 MALDI-TOF MS 
1.4.1 Background 
Mass spectrometry (MS) was discovered in the early 1900s and was mostly applied in the chemical 
field. MALDI-TOF followed in the 1980s, and allowed MS to be applied to larger biological molecules 
such as proteins (26). MALDI-TOF MS has since proven to be a powerful tool for the reliable 
identification of bacteria and yeast from solid culture media plates in the clinical laboratory (1,67).  
1.4.2 Principle 
MALDI-TOF technology is a method used to determine the protein composition of an isolate and 
allows the comparison of the resulting protein spectrum to a commercial database for organism 
identification. The basic procedure involves mixing a pure culture of the isolated bacterium with a 
matrix compound and allowing it to dry on a conductive target slide to enable crystallisation of the 
mixture. The target slide is introduced into a high vacuum environment and the isolate/matrix mixture 
is subjected to an ultraviolet laser beam which fires brief laser pulses through the sample. The 
excitation of the matrix causes sublimation from the solid phase to the gaseous phase. Matrix 
molecules and microorganism proteins are released from the surface of the target slide (desorption) 
and protons from the matrix are transferred to the proteins which result in a positively charged protein 
molecule in the gaseous phase (ionisation). 
 
This “cloud of proteins” enters an electrostatic field and with a high voltage supply, the ions are 
introduced into the high vacuum flight tube where they are separated according to their mass to 





of the flight tube to create a spectrum that represents the protein constituents of each sample. This 





Figure 1-3 Principle of Matrix-assisted laser desorption ionisation-time of flight methodology (68) 
 
The resultant protein profile is considered the fingerprint of the microorganism and the protein 
spectrum is displayed with the m/z (mass-to-charge ratio) values along the x-axis and the intensity 
of the signal plotted against the y-axis (68) (see Figure 1-4 for an example).  
 







Figure 1-4 Spectral fingerprint from Vitek Mass Spectrometry of members of the M. avium complex (69) 
 
1.4.3 Available MALDI-TOF systems 
There are three commercial MALDI-TOF systems currently available (2019) which include the 
Andromas (Andromas Paris, France), Vitek MS (bioMérieux, France) and the Bruker Biotyper 
(Bruker Daltonics, Germany) instruments (59). 
The Vitek MS and Bruker Biotyper are the only systems currently available in South Africa. Although 
all of these systems have been evaluated in the past, most published studies refer to the Bruker 
technique (14,70). The Bruker Biotyper and Vitek MS differ in extraction methods, database 
construction and evaluation of results (24,59).  
 
In 2017 bioMérieux expanded the In-vitro Diagnostic- European Conformity (IVD-CE) marked VITEK 
MS® database to include Mycobacteria, Nocardia and moulds (which includes dermatophytes and 
dimorphic fungi). This version (v3.2) of the database allows for the identification of 242 new bacterial 
(including 39 mycobacteria taxa [comprised of 49 total species] and 15 Nocardia spp.) and 55 new 
fungal species. Refer to Appendix B for a list of organisms included in the Vitek MS Knowledge Base 
(KB) v3.2. With this database update, two reagent kits were introduced: the VITEK MS® 
Mycobacterium/Nocardia kit (bioMérieux, France, Ref 415659) and the VITEK MS® Mould kit 
(bioMérieux, France, Ref 415680). Testing is performed from organism growth on solid media. In 
addition to the VITEK MS® Mycobacterium/Nocardia kit, a Liquid Myco Supplemental kit (bioMérieux, 






1.4.4 MALDI-TOF MS identification of nontuberculous Mycobacterium 
The application of MALDI-TOF for the identification of Mycobacterium spp. began over a decade 
ago, but the technique used for the identification of bacteria and yeast involving the direct spotting 
of the cultured organism onto a MALDI-TOF target slide was not suitable (5,45). The cell wall of 
Mycobacteria contains lipids and peptidoglycans esterified with mycolic acids which creates a 
hardiness to the cell wall with a low permeability. Due to the cell wall constituents and the 
pathogenicity of Mycobacteria, an inactivation and extraction step is necessary to release the 
contents within the cells (25,45,71).  
 
Literature review does not provide a clear protocol for the identification of Mycobacteria from liquid 
cultures, but bioMérieux has standardised the procedure by providing a commercial kit for the 
standardisation of the method. 
 
1.4.5 MALDI-TOF MS identification of Nocardia 
Following genomic methods for the identification of Nocardia spp., proteomic methods have been 
evaluated for this purpose (38). Bacteria and yeast can be identified by using the direct spotting 
technique but this is not applicable for Nocardia (45) due to the presence of aliphatic acids in the cell 
wall which renders a complication for achieving acceptable protein profiles (38). To overcome this 
burden, mechanical disruption and a protein extraction step is needed when processing Nocardia 
spp. for identification using the MALDI-TOF technology (45). 
 
MALDI-TOF has been in use for many years for the identification of Nocardia spp., but there is a 
significant variability in the performance as well as in test methodologies used (45). Deficiencies in 
the available reference databases and the non-standardised methodologies may have contributed 
to this variability in test performance (2) which varies from 41.9% - 90.6% of identification to species 
level (1,38,72). It is evident from recent research that well-curated and validated databases are 
needed to account for the variability that is encountered in the protein spectra (45). Another aspect 
to consider is the complementation of the reference database with “in-house” protein profiles, relying 
on local epidemiology knowledge, and hence, may assist with the identification to genus level, or 
even species level (38). 
 
Due to the limited amount of studies available on the Vitek MS for the identification of Nocardia spp. 






1.4.6 MALDI-TOF MS identification of moulds 
Fungi are biologically complex organisms and different phenotypes (hyphae and/or conidia) co-exist 
in the same organism (26), which produces protein spectra that may vary. Substantial spectral 
varieties have been noted between different stages of fungal growth of the same isolate and between 
subcultures of the same strain (51). This has led to a slower implementation rate of the MALDI-TOF 
MS technology for the identification of fungi than for bacterial identification in the clinical laboratory 
(26).  
 
The cell wall of fungi differs significantly from that of bacteria in that it consists mostly of 
polysaccharides, including chitin and glycoproteins (51). Identification of filamentous fungi on the 
MALDI-TOF MS requires additional processing steps to disrupt the cell wall, extract the proteins and 
to inactivate the organism. This has contributed to the slower implementation rate of this technology 
into the clinical laboratory (73). There are also aspects of processing moulds for MALDI-TOF MS 
that may influence the spectrum profile, including different maturation stages of selected colonies, if 
conidia are present or not; and the presence of melanin in some moulds that may interfere with 
ionisation (58). 
The MALDI-TOF MS instrument has reduced the turnaround time for the identification of moulds 
although the technology is still dependent on fungal cultures (59). The benefits for using the MALDI-
TOF MS for the identification of filamentous fungi is the ability to report to a species level and the 
identification of isolates that do not produce the morphological structures required for traditional 
identification methods, for example the sterile moulds (51,74). Furthermore, relying on the protein 
profiles of a MALDI-TOF MS  is more objective than phenotypic methods of mould identifications, 
which is dependant on the users interpretation skills.  
 
MALDI-TOF MS protein extraction is particularly complex and can result in diverse levels of 
performance depending on the sample type used for extraction (whole mould versus spores) and if 
solid or liquid media has been used. All of these result in different spectrums influencing the results 
and are dependent on the database coverage (74). MALDI-TOF MS is simple to use and for this 
reason technologists may never develop the skills or lose the ability to visually identify fungi 
macroscopically and microscopically, which may pose a problem during possible instrument 
downtime and loss of skilled technologists (24).    
 
1.5 Problem statement 
While various laboratory methods exist for the identification of NTMs, Nocardia and moulds, most 
rely on culture of the organism which can lead to significant delays in diagnosis. Average turn-around 





and fast-growers) and 1 to 4 weeks respectively. The identification of these pathogens is of clinical 
importance as it influences the selection of drugs used for treatment of these particular infections. 
Speciation of these organisms by phenotypic methods requires technically competent staff. Mould 
identification is particularly challenging as it is based on the subjective morphological 
characterisation of colonies, hyphae and spores (47,75).  
 
Molecular methods offer an advantage in that they can decrease turn-around times to less than 3 
days and are not as subjective as phenotypic classification systems. However, the majority of 
commercially available molecular assays target a limited range of organisms per assay, depending 
on the detection method used. DNA sequencing methodologies targeting hypervariable regions 
unique to bacterial and fungal species allow identification of a broader range of organisms (including 
potentially novel organisms). However, these methods require expensive equipment and reagents 
as well as highly skilled staff; and are therefore not commonly performed in smaller clinical 
laboratories (1,5). Pan-fungal and 16S rRNA (bacterial) sequencing also requires single organism 
infections as multiple infections will interfere with result interpretation. 
 
Matrix-assisted laser desorption ionisation-time of flight mass spectrometry (MALDI-TOF MS) is a 
rapid and relatively simple method to perform for the identification of organisms in clinical 
microbiology laboratories. Although the initial placement of the instrument is expensive, the 
continuous use with consumables is very cost-effective (5,67).  The method is currently used in our 
setting and has shown potential in publications for use in speciation of NTMs, Nocardia and moulds. 
There is  a need to investigate which of these methods would be most suitable to a clinical diagnostic 
(reference laboratory) setting, taking performance, turn-around time, ease of use and cost analysis 
into account. 
 
1.6 Aim and objectives 
The aim of this study was to compare the Vitek MALDI-TOF MS (bioMérieux, France) to various 
phenotypic and/or hybridisation and sequencing based molecular assays, in order to identify the 
most suitable assay to speciate NTM, Nocardia and moulds in a reference laboratory setting.  
 
The objectives included: 
a) Optimisation of the Vitek MS method for NTM, Nocardia and mould identification 
b) Comparison of the performance, workflow impact and crude cost of the Vitek MS method to 
the following NTM identification methods: 





c) Comparison of the performance, workflow impact and crude cost of the Vitek MS method to 
the following mould identification methods: 
i) Mycology (Culture and Microscopy) 
ii) ITS Pan-Fungal sequencing 
d) Comparison of the performance, workflow impact and crude cost of the Vitek MS method to 
the following Nocardia identification methods: 
i) 16S rRNA sequencing 
ii) Nocardia  specific Multi-Locus Sequence Analysis  
 
1.7 Ethical approval 
Ethical approval (Reference #: S18/10/208) was obtained from the Health Research Ethics 
Committee (HREC) from Stellenbosch. This was a laboratory based study. The organism 
identifications were performed on clinical isolates derived from routine laboratory procedures or 
retrospectively. All investigators are healthcare professionals registered with the HPCSA as well as 
PathCare employees bound by confidentiality agreements. Samples were anonymised for reporting 
in the thesis, and patient management was not affected by any of the results. Although results were 
available prior to testing on the Vitek MS, this lack of blinding did not have any affect on the outcome 
of results as the Vitek MS software provides an objective report and is not interpreted by the user. 
 






 IDENTIFICATION OF NONTUBERCULOUS 
MYCOBACTERIUM 
2.1 Introduction 
The objective of this chapter was to evaluate the performance of the Vitek MALDI-TOF MS for the 
identification of NTMs by comparing the results to molecular hybridisation-based techniques such 
as the Genotype Mycobacterium CM / AS assays. 
2.2 Materials and methods  
2.2.1 Sample selection 
78 NTMs isolated from consecutive clinical samples (January to September of 2019) were identified 
in the PathCare Reference Laboratory as part of routine clinical care using the Hain Mycobacterium 
CM and AS kits, according to the manufacturer’s instructions.  
 
Briefly, positive MGIT cultures (with positive ZN) were sent for MPT64 antigen (Beckton Dickenson, 
United States) testing to guide downstream analysis. Positive MGIT cultures presenting with a 
negative ZN were excluded from the study. MPT64 positive samples (indicative of M. tuberculosis 
complex) were excluded from the study. MPT64 negative samples (suggestive of NTMs) were 
included in the study for further testing by the Genotype Mycobacterium CM assay which speciates 
the more common NTMs. Where speciation was not resolved using the CM assay, the Genotype 
Mycobacterium AS assay was used which targets the less common NTMs. 
 
The current PathCare laboratory workflow (applicable to this study) for the identification of NTMs is 
visualised in Figure 2-1.  
 





2.2.2 Genotype Mycobacterium CM / AS assay 
 DNA extraction 
DNA was extracted using a crude boil method (PathCare validated package insert deviation): the 
positive MGIT culture tube was vortexed adequately after which 2ml fluid was transferred into a 
labelled screw cap Eppendorf tube. The tube was centrifuged at 14 000 rpm for 5 min and the 
supernatant was carefully removed using a sterile pastette without disturbing the pellet. 200μl of 
PCR grade dH2O, containing 4 μl Internal Control DNA (IC), was added and the sample was vortexed 
to resuspend the pellet. The Eppendorf tube was incubated at 100° C in a heating block for 30 
minutes to inactivate the organism. After the incubation period, the sample was cooled down for 5 
minutes at room temperature and centrifuged at 14 000 rpm for 5 minutes. The supernatant was 
used as a template for the PCR reaction. 
 DNA amplification 
The supplied Hain Mycobacterium Amplification Mixes A and B (AM – A and AM – B) contain all the 
required biotinylated primers and polymerase for the reaction to produce biotinylated amplification 
products. The stored Amplification Mixes (-20°) were thawed at room temperature and carefully 
mixed by pipetting up and down. 
 
The amplification master mix was prepared by adding 10μl of AM-A and 35μl of AM-B to a PCR 
reaction tube,  after which 5μl of sample DNA was added (final reaction volume was 50μl). To prevent 
cross-contamination, the DNA extraction, preparation of amplification mixes and addition of sample 
DNA; and the hybridisation step were done in separate rooms.  
 
Thermal cycling was conducted in an Applied Biosystems (AB) Proflex thermal cycler according to 
the manufacturer’s (Hain LifeSciences, Germany) recommended touch-down profile: initial 
denaturation at 95°C for 15 minutes followed by 10 cycles of denaturation at 95°C for 30 seconds 
and annealing at 65°C for 2 minutes; and 20 cycles of denaturation at 95°C for 25 seconds, annealing 
at 50°C for 40 seconds and elongation at 70°C for 40 seconds. The thermocycling was completed 
with a final extension step at 70°C for 8 minutes (Heating/Ramp rate of ≤2.2°C/sec).  
 Denaturation and hybridisation 
The amplification products were chemically denatured on the GT-Blot-48 automated analyser 
according to the manufacturer’s instructions, and the single stranded amplicons underwent reverse 
hybridisation to specific probes present on the Hain membrane strip, which were subsequently 






Resultant hybridisation patterns were used to speciate the NTM. Amplification and hybridisation 
procedures are the same for the Mycobacterium CM and AS assays, therefore amplicons could be 
used interchangeably with the kit specific hybridisation strips. 
 Quality control 
Each Genotype Mycobacterium test strip contains three control probes which are included to monitor  
the performance and functioning of the contents of the manufacturer’s kit. Figure 2-2 indicates the 
three control areas. The Conjugate Control (CC) indicates the efficiency of binding of the conjugate 
on the strip and controls for a correct chromogenic reaction. The Internal Control (IC) reveals 
effective DNA extraction and amplification. The Genus Control (GC) show the presence of a member 
of the genus Mycobacterium.  
 
A negative control was added to each batch of samples run to test for possible contamination. This 
control sample was processed from the extraction step as per the study samples and was expected 
to only show hybridisation for  the IC and CC zones. If not, the whole run was considered invalid and 
was repeated. A separate positive control was not included as this was deemed optional by the 
manufacturer. We deemed the 3 hybridisation strip controls to be a suitable substitute for the positive 
control as we had already pre-screened MGIT cultures using ZN microscopy and an MPT64 antigen 
assay. 
 Evaluation and interpretation of results 
Each Genotype Mycobacterium test strip contains 17 reaction zones, which included the three 
control zones: CC,IC and GC. 
 
Figure 2-2 Layout of the Genotype Mycobacterium CM / AS test strip (76) 
 
A correctly performed test would result in the binding of a control amplicon to the IC probe. A valid 





If the IC band failed to develop in a negative test result, the test result was deemed invalid, either 
due to inhibition of the amplification or errors made during DNA extraction or amplification. 
The signal strength on all the bands may differ and only those bands that showed similar or stronger 
intensities than the IC were considered. Figure 2-3 and Figure 2-4 represent the result interpretation 
of the Genotype Mycobacterium CM / AS assays. 
 
 
Figure 2-3 Genotype Mycobacterium CM result interpretation chart (76) 
 





2.2.3 Extraction and inactivation protocol for MALDI-TOF MS 
The extraction and inactivation of NTMs was done in a Biosafety Level 2 environment according to 
the manufacturer’s instructions using the Vitek MS Mycobacterium/Nocardia kit (Ref: 415659). Once 
the inactivation step was completed, the rest of the process was conducted outside the Biological 
Safety Cabinet (BSC). 
 
The process involved a centrifugation step of 3ml MGIT fluid for 10 min at 3000 x g after which the 
inactivation step was performed by adding 500µl of 70.0% Ethanol to the pellet, transferring the 
mixture to a supplied tube containing beads and vortexing horizontally on a Genie 2 vortex for 15 
min. The inactivation was concluded with an incubation period (tube in vertical position) for 10 min 
at room temperature. Following centrifugation for 2 min at 14 000 x g (Hermle Microliter Centrifuge 
Z233 M-2), the extraction was performed by adding 10µl of 10.0% Formic acid and 10µl of 100.0% 
Acetonitrile to the pellet. The process was concluded with a final centrifugation step for 2 min at 
14 000 x g. The DS target slide was prepared by transferring 1 μl of the supernatant in duplicate to 
the target slide and left at room temperature to air dry. Each dried sample spot was overlaid with 1µl 
of α-Cyano-4-hydroxycinnamic acid (CHCA) matrix and left to air dry after which the slide was 
processed on the Vitek MS within 72 hours (as per the manufacturer’s instructions). The spectra of 
the target slides were acquired using the Vitek MS Prep and  Acquisition Stations (bioMérieux, 
France); and Spectra were analysed using Myla software with Knowledge Base (KB) v3.2.0. 
 
As recommended by the manufacturer, the Escherichia coli ATCC 8739 strain, used as a calibrator 
and internal identification control, was inoculated on the calibration spots of each acquisition group. 
Negative and positive controls were included in each batch of samples prepared. The negative 
control used consisted of reagents only and the positive controls included M. smegmatis ATCC 
2415119 or M. intracellulare ATCC 13950 grown on Lowenstein-Jensen medium (LJ). 
 
Deviations to the manufacturer’s protocol involved centrifugation of 1.5ml MGIT fluid twice in 2 ml 
Eppendorf tubes, or centrifugation of 3 – 5.5 ml in 50ml conical tubes, rather than the recommended 
3ml in a 5ml tube. In addition, all vortex steps were done without the mobio-adapter, due to this 
device not being available during the course of the study. However, we felt that we were able to 
simulate a similar vortexing effect by securing the tubes with parafilm horizontally on the platform 
head. 
 
MGIT tubes were initially processed following storage at room temperature for between 4 – 31 days 
(Method 1) (23). In an attempt to optimise results we examined the effects of different incubation 





• Method 2: MGIT tubes incubated at 37°C between 24-72 hrs post positivity (package insert, 
bioMérieux, France) and 1.5ml MGIT fluid centrifuged twice in 2 ml Eppendorf tubes. 
• Method 3: 3-5 ml MGIT fluid centrifuged in 50 ml conical tube with the same incubation 
conditions as Method 2  
• Method 4: 5.5 ml MGIT fluid centrifuged in 50 ml conical tubes after a 6 day incubation period 
at 37°C post positivity (5).  
 
These methods were not run in parallel on all samples, but were done in a sequential fashion as part 
of a running optimisation of an ideal protocol, therefor, the difference in sample sizes. 
 
2.3 Results and discussion 
A total of 78 isolates identified as NTMs by the Genotype Mycobacterium CM / AS assays were 
extracted and processed for identification on the Vitek MS by either one of the four methods 
described in section 2.2.3.  Table 2-1 lists the organisms tested with each method and the results 




























       Table 2-1 Nontuberculous mycobacteria Vitek Mass Spectrometry identification results 
 Samples highlighted in blue represent samples that correlated with the laboratory reference method 
 Samples highlighted in orange represent samples with “no identification” (good spectrum) 
 Samples highlighted in green represent samples with “no identifications” (bad spectrum) 
 Samples highlighted in grey represent contaminated samples 
Study 
Key 
TB Lab ID - Hain Duplicates† Vitek MS Correlate? Method 
1 M. abscessus complex a-b M. abscessus Yes 1 
2 M. abscessus complex a-b M. abscessus Yes 1 
3 M. fortuitum a-b M. fortuitum group Yes 1 
4 M. avium a-b M. avium Yes 1 
5 M. kansasii a-b M. kansasii Yes 1 
6 M. gordonae 
a M. gordonae 
Yes* 
1 
 b No identification 
7 M. intracellulare 
a No identification 
Yes* 1 
b M. intracellulare 
8 M. fortuitum 
a M. fortuitum group 
Yes* 2 b No identification 
reshoot a-b  Bad spectrum 
9 M. avium 
a M. avium 
Yes* 2 
b No identification 
10 M. kansasii 
a M. kansasii 
Yes* 2 
b Background noise 
11 M. fortuitum 
a-b Not enough peaks 
Yes* 2 
c-d M. fortuitum group 
12 M. avium 
a Bad spectrum 
Yes* 3 
b M. avium 
13 M. fortuitum a-b M. fortuitum group Yes 4 
14 M. fortuitum a-b M. fortuitum group Yes 4 
15 M. gordonae 
a-b M. gordonae 
Yes 4 
reshoot a-b Bad spectrum 
16 M. intracellulare 
a-b M. intracellulare 
Yes 4 
reshoot a-b Bad spectrum 
17 M. avium 
a M. avium 
Yes* 4 
b No identification 
18 M. fortuitum a-b No identification No 1 
19 M. avium a-b No identification No 1 
20 M. gordonae a-b No identification No 1 
21 M. kansasii a-b No identification No 1 
22 M. malmoense a-b No identification No 1 
23 M. intracellulare a-b No identification No 1 
24 M. gordonae 
a No identification 
No 1 
b Bad spectrum  





b Bad spectrum  
26 M. malmoense 
a-b No identification 
No 1 
c-d Bad spectrum  
27 M. fortuitum a-b No identification No 2 
28 M. avium a-b No identification No 2 
29 M. avium a-b No identification No 2 
30 M. intracellulare a-b No identification No 2 
31 M. intracellulare a-b No identification No 2 
32 M. intracellulare a-b No identification No 2 
33 Mycobacterium spp.  
a-b No identification 
Possible** 2 
reshoot a-b Background noise 
34 Mycobacterium spp.  a-b No Identification Possible** 2 
35 Mycobacterium spp.  a-b No identification Possible** 2 
36 Mycobacterium spp.  a-b No identification Possible** 2 
37 M. fortuitum 
a Bad spectrum  
No 2 
b No identification 
38 M. avium 
a Bad spectrum  
No 2 
b No identification 
39 M. kansasii 
a Bad spectrum  
No 2 
b No identification 
40 M. fortuitum a-b No identification No 3 
41 Mycobacterium spp.  
a-b No identification 
Possible** 3 reshoot a Bad spectrum 
reshoot b Too many peaks 
42 M. scrofulaceum a-b No identification No 3 
43 M. intracellulare a-b No identification No 4 
44 M. malmoense a-b No identification No 4 
45 M. intracellulare a-b No identification No 4 
46 M. intracellulare a-b No identification No 4 
47 M. intracellulare a-b No identification No 4 
48 Mycobacterium spp.  a-b No identification Possible** 4 
49 M. intracellulare 
a No identification 
No 4 
b Bad spectrum 
50 M. intracellulare 
a No identification 
No 4 
b Bad spectrum  
51 M. scrofulaceum 
a Bad spectrum  
No 4 b No identification 
reshoot a-b Bad spectrum 
52 Mycobacterium spp.  
a No identification 
Possible** 4 
b Bad spectrum  
53 M. kansasii a-b Bad spectrum  No 1 
54 M. kansasii a-b Bad spectrum  No 1 
55 M. intracellulare a-b Bad spectrum  No 1 





57 M. kansasii a-d Bad spectrum  No 1 
58 M. intracellulare a-d Bad spectrum  No 1 
59 M. avium a-b Bad spectrum  No 2 
60 M. avium a-b Bad spectrum  No 2 
61 M. intracellulare a-b Bad spectrum  No 2 
62 M. intracellulare a-b Bad spectrum  No 2 
63 M. kansasii a-b Not enough peaks No 2 
64 M. intracellulare a-b Background noise No 2 
65 M. fortuitum 
a Bad spectrum  No 
2 
b Not enough peaks No 
66 M. avium a-d Not enough peaks No 2 
67 M. intracellulare a-d Bad spectrum  No 2 
68 Mycobacterium spp.  a-b Bad spectrum  No 3 
69 Mycobacterium spp. a-b Bad spectrum  No 3 
70 M. avium a-b Bad spectrum  No 3 
71 M. intracellulare a-b Bad spectrum  No 3 
72 Mycobacterium spp.  a-b Bad spectrum  No 4 
73 M. gordonae a-b Bad spectrum  No 4 
74 M. intracellulare a-b Bad spectrum  No 4 
75 M. intracellulare a-b Bad spectrum  No 4 
76 M. intracellulare a-b Bad spectrum  No 4 
77 M. intracellulare 
a E. faecalis 
No 2 
b No identification 
78 M. kansasii 
a Not enough peaks 
No 2 b 
E. asburiae 
E. cloacae  
c-d No identification 
† a-b duplicate spots from initial run; c-d duplicate spots from repeat run  
* Consensus correlates (best result of a repeat / duplicate spot was considered correct) 
** Considered a possible correlation as a “no identification” (good spectrum) result is expected in cases where the organisms 
are represented in the Vitek MS database. 
 Methods 1 – 4, see section 2.2.3 
 
According to the Mycobacterium CM/AS classification, only 16.7% (13/78) belonged to the fast 
growing NTM group with the remaining 83.3% (65/78) classified as slow growers. 
 
Of the 78 isolates tested by either one of the 4 methods, 21.8% (17/78, CI95%:12.6% - 31.0%) 
correlated 100% with the Vitek MS (confidence level of 99.9%). The method that delivered the 
highest percentage of identifications was Method 1 (7/22, 31.8%) followed by Method 4 (5/20, 25%), 
Method 2 (4/28, 14.3%) and then Method 3 (1/8, 12.5%). Method 3 performed particularly poorly and 
we therefore halted any further testing of that method. As we did not perform all 4 methods on each 
of the 78 isolates, we analysed the data to determine if there was a clustering effect of any of the 





but no possible association to better performance could be made due to low numbers included in 
the study. There was overrepresentation of M. intracellulare in Method 4, which performed poorly as 
a whole. Many of these isolates resulted in “no identifications” despite being represented in the 
database.  
 
The low percentage of identifications obtained in this study correspond to previous publications were 
the MALDI-TOF MS system failed to identify NTMs (78). In contrast, subsequent studies report 
identification rates ranging from 83.9% to 97.6%. The manufacturer, using what we describe as our 
Method 2, reported 87.7% (64/73, CI95%: 77.9% - 94.2%) correct identifications, 2.7% (2/73, CI 95%: 
0.1% - 6.5%) incorrect identifications and 9.6% (7/73, CI95%: 2.8% - 16.3%) “no identifications’ 
(6,10,79).  
Our study results  for Method 2 were statistically different to the manufacturer’s results for correct  
(P = <0.001, 87.7% [bioMérieux] vs 14.3% [our study]) and “no identifications” (P = <0.001, 9.6% 
[bioMérieux] vs 85.7% [our study]). There was however,  no statistical difference between the 
number of incorrect identifications (P = 0.1411, 2.7% [bioMérieux] vs zero [our study]) obtained. 
We do not believe that included strain types were responsible for variations in findings as both 
studies (manufacturer and ours) consisted predominantly of M. avium and M. intracellulare.. 
 
There is a possibility of cross-identification between the Vitek MS displayed taxa (organism present 
in database) and unclaimed taxa (i.e. not present in the database, but may be reported as the 
corresponding displayed taxa). Table 2-2 lists the cross-identifications which may have affected this 
study. 
 
Table 2-2 Vitek Mass Spectrometry Nontuberculous mycobacteria possible cross-identifications  
applicable to this study 
Vitek MS Displayed taxa 
(Reported by Vitek MS) 
Possibility of (Unclaimed taxa) 
M. abscessus 
M. abscessus spp. abscessus 
M. abscessus spp. bollettii 
M. abscessus spp. massiliense 
M. avium 
M. avium spp. avium 
M. avium spp.  paratuberculosis 
M. avium spp. silvaticum 
M. avium spp. chimaera 




M. yongonense / marseillense 










As seen in Table 2-2 there can be a cross-identification between  M. intracellulare and M. avium but 
both these organisms belong to the M. avium complex (MAC). The virulence of the two species 
depends on the underlying disease and the presence of co-morbidities e.g. M. intracellulare has a 
higher pathogenecity in cancer patients than M. avium (80). Patients with pulmonary disease caused 
by M. intracellulare are less likely to have a clinical relapse or reinfection after antiobiotic treatment 
than other species in the MAC group. As treatment options are similar for these two organisms, 
speciation has a prognostic benefit regarding disease severity and recurrence (81,82). Although 
these cross-identifications can occur it had zero impact on our study as all identifications correlated 
100% with the reference method and no cross-identifications occurred.  
 
78.2% (61/78, CI95%: 69.0% - 87.4%) resulted in a “no identification” result (samples 18-78, Table 
2-1). This is in contrast to the 9.6% of “no identification” reported by the manufacturer. Of these 61 
samples, 60.7% (37/61) showed good quality spectrums, implying that there were more than 30 
protein profiles that passed internal quality control (QC) (samples 18-52). These should have 
resulted in a successful identification if the organism was represented in the database. Interestingly, 
most of our results showed good quality profiles, but failed to generate an identification despite the 
expected organisms being represented in the database.  
 
An advantage of the Genotype Mycobacterium CM /  AS assays over the Vitek MS is that when a 
species is not represented in the Vitek MS database, resulting in a “no identification” (good quality 
spectrum), the CM/AS assay will still allow identification up to the genus level. Ten samples were 
reported as Mycobacterium sp. following the Mycobacterium CM and AS assays as they did not fall 
into one of the species targeted by the assays. Of these the Vitek MS obtained “no identification” 
results of which 70.0% (7/10) were due to good quality spectrums. A “no identification” (good 
spectrum) result may be due to the organism not being represented in the Vitek MS KB, however 
we were unable to confirm for these 7 cases if this was the reason for the “no identification” result 
as we were unable to speciate them with the reference method.   
 
MALDI-TOF MS is designed for use on pure cultures and is incapable of distinguishing between 
individual components of a polymicrobial culture. The presence of more than one Mycobacterium 
spp. can therefore not be excluded, however, this is not the case with the Genotype Mycobacterium 
CM / AS assays, where you be able to interpret some mixed infections by analysing the mixed 
Vitek MS Displayed taxa Possibility of (Displayed taxa) 
M. avium M. intracellulare 





hybridisation patterns. The Vitek MS identification result will depend on the protein concentration 
which will most likely be dominated by the  faster growing organism (21). Two contaminated samples 
in our study were identified by the Vitek MS as bacteria not belonging to the genus Mycobacteria 
(samples 77-78), both of these cases identified organisms with much faster growth rates than 
Mycobacteria. In contrast, the Genotype Mycobacterium CM / AS assays were not affected (14) as 
an Mycobacterium identification was achieved.  
 
Eight samples (samples 11, 26, 56-58, 66-67, 78; Table 2-1) which initially did not provide an 
identification were repeated and only 12.5% (1/8) isolate (sample 11) could be resolved (M. 
fortuitum). The no identifications were mainly due to bad spectrums or not enough peaks, while only 
1 sample was due to a good quality spectrum (sample 78 which showed a mixed infection). 
 
It was evident in the early stages of the study that suboptimal results were being obtained due to the 
numerous “no identifications” by the Vitek MS system, despite good quality spectrums. 
Troubleshooting, in conjunction with bioMérieux South Africa and France, involved confirmation of 
the correct procedure, including the need for horizontal vortexing (15 min), exact centrifugation times 
and settings, complete ethanol removal and the spotting of the supernatant and not the pellet onto 
the target slide. bioMérieux analysed assay run files of “no identification” results and determined that 
the instrument was not sensitive enough to detect all the protein peaks to make an identification. 
The extraction method did not appear to be at fault. The instrument was therefore fine-tuned a 
number of times to improve the sensitivity. This involved adapting instrument settings while running 
a control strain. The linear detector of the system has a decreased sensitivity with increased use due 
to the ions impacting the detector. Consequently, fine tuning is required on a regular basis of which 
the frequency is determined by the throughput of the laboratory as well as the quality of the calibrator 
selected.  
Similar problems were encountered by the routine diagnostic laboratory when testing bacterial and 
yeast isolates at the time and included extremely slow acquisition and failed calibrations in Myla 
despite appearing to pass  during acquisition. The linear detector was replaced  and although there 
was a slight improvement in the number of identifications obtained after each fine-tuning intervention, 
the problem was not permanently resolved. Several slides (samples 8, 15, 16, 33, 41, 51) were 
reshooted  on two different Vitek MS instruments (including one at a different pathology practice). 
Initial identifications (e.g. M. intracellulare and M. gordonae) and  “no identifications” (good 
spectrums) resulted in bad spectrums with the reshoot. This strongly indicates that even though a 
bad spectrum result may be resulted on one instrument, that another may be able to report a species 






The remaining 39.3% (24/61) “no identification” results (samples 53-66) were due to bad spectrums 
(i.e. <30 spectral peaks) and were subsequently reported as either (a) bad spectrum during 
acquisition, (b) too few or (c) too many poor quality peaks or (d) background noise (14) by the Myla 
software. “Bad spectrum” results may be due to a number of reasons including: 
• insufficient growth of the organisms and a subsequent suboptimal limit of protein to be 
analysed; or conversely, 
• overgrowth of the organisms which result in inactivation of the genes encoding protein 
syntheses, with subsequent lysis of proteins already present in the culture (MGIT cultures 
only) (Personal communication, bioMérieux).  
 
The Vitek MS KB database was constructed with protein profiles of organisms in the log phase of 
growth (6). It was therefore essential to test the organisms during this phase. Despite adapting the 
protocol to include an additional incubation step of 24 to 72 hours at 35 ± 2°C post MGIT incubation, 
we did not see an improvement in results.  
A previous study by Huang et al. showed that there was no association between the duration of 
culture positivity and the success of rapid growing mycobacteria identification using a time frame of 
0 to 6 days, however, the majority of our identifications were for slow-growing mycobacteria. They 
reported that slow-growing mycobacteria showed an increase in successful identifications with the 
increased number of incubation days post positivity (21 days) at room temperature. (21). A similar 
approach was reflected as Method 1 which yielded the most identifications of the 4 methods. 
 
A further attempt to improve assay performance included increasing the biomass (Method 3, section 
2.2.3), although it did not lead to an increased assay performance. Some samples contained less 
biomass than others and did not create an obvious pellet after the initial centrifugation step, 
especially M. intracellulare of which 41.8% (23/55) were included in the slow growing group tested.  
The identification of fast growers (53.8%) compared to the the slow growers (18.2%) strongly 
suggests that incubation time and resultant biomass (i.e. pellet size) may be crucial contributors to 
the success of identification obtained (21).  
 
Garner et al. 2019 showed that an increased biomass led to 100.0% accurate identification rates 
with no “no identification” results (personal communication, Dr Garner, University of California, Los 
Angeles). This was achieved by adapting bioMérieux’s protocol (Method 2 of this study) by 
incubating MGIT tubes 6 days post positivity and processing 6 ml fluid (Method 4 of this study). They 
tested 51 NTM isolates, of which the majority were slow growers (29 /51, 56.9%) (83), and 22 (22/51, 
43.1%) fast growers. Our study included only 13 (13/78, 16.7%) fast growers. The organism mostly 
isolated in their study belonged to the slow grower M. simiae complex (12/51, 23.5%) which was not 





M. chelonae (5/51,9.8%), M. mucogenicum complex (10/51, 19.6%) and M. arupense (2/51, 3.9%). 
A limitation of the study is their data did not include M. intracellulare which was the most isolated 
organism in our study. Ten of the 20 (10/20, 50.0%) samples tested following the protocol proposed 
by Garner et al. were M. intracellulare (Method 4). The fact that our study did not replicate the 
success experienced by Dr Garner and his team could suggest that the root cause of the problems 
experienced may be far deeper than obtaining sufficient biomass.  
 
Buckwater et al. suggested that interfering substances present in MGIT tubes may have an adverse 
effect on test results (1). Our results support this as we were able to successfully identify NTM ATCC 
strains from solid Lowenstein-Jensen media (LJ), but failed to obtain results when tested from liquid 
MGIT media. Identifications could only be obtained by increasing the processing volume of MGIT 
cultures to 5 ml, however, we were unable to resolve patient samples in this way. A possible 
explanation for this is that the QC MGIT tubes lack normal flora and cell debris normally present in 
patient samples which may have affected identification (6).  
However, the performance characteristics for Mycobacterium liquid cultures from clinical specimens 
is documented in the Vitek MS user manual as 87.7% (64/73) with 2.7% (2/73) incorrect 
identifications and a total of 9.6% (7/73) no identifications.  
A limitation of our study was processing samples without the recommended mobio-adapter (Figure 
2-5) and it cannot be excluded that it contributed in obtaining less proteins required for an 
identification. However, we were able to mimic the positioning of samples on the same vortex and 
obtained satisfactory results when tesing quality control strains.  
 
 
Figure 2-5 Genie 2 vortex with attached mobio-adapter 
 
Furthermore, centrifuge rotors for 5ml tubes were not available in our setting and samples were 
processed in eppendorf or conicle tubes. The outcome of the results were not significantly affected 
by applying different tube sizes. However, we are confident that these deviations did not significantly 
affect the results of the study.  
The poor results (particularly the high rate of “no identifications” in our study and issues with the 
routine microbiology bacterial identifications) were further investigated by bioMérieux. In an attempt 





company further suggested to allocate dedicated staff members to apply calibration spots and 
adapting some of the routine microbiology procedures including: (a) correct maintenance, storage 
and reculture of the E.coli ATCC 8739 strain (Appendix C) used during rolling calibration checks or 
the manual calibration / fine tuning of the instrument; (b) spot preparation to add matrix to each spot 
as they are processed, and not per batch, as this would affect crystalisation. 
 
However, despite all interventions, no improvement in the instrument performance was seen. 
bioMérieux did a TOF/BSA (Bovine serum albumin) test on the two instruments and the problem was 
suspected to be software related. This finding fits in perfectly with the “no identification” (good 
spectrum) results obtained in our study as the software was unable to read the protein profiles 
effectively to supply an identification despite the organisms theoretically being represented in the 
Vitek MS KB software. The problem was unfortunately not rectified at the time of thesis submission. 
 
2.4 General workflow and cost analysis 
The workflow on the Vitek MS for organism identification was examined by calculating the amount 
of time needed for hands-on and hands-off procedures for the method. Calculations were done using 
Microsoft Excel,v.1904 (Microsoft, Washington) and included factoring in the number of control 
samples per batch. 
 
The process was broken down into three steps for which the duration was recorded: 
• Sample processing - included the time from the start of processing the isolates until the 
supernatant was spotted onto the target slide. The time allocated to hands-on procedures 
was determined as the total sample processing time, less the fixed hands-off time. Hands off 
time included bead beating, incubation and centrifugation steps.  
• Target slide drying - included the time the supernatant was first spotted onto the slide until 
ready for processing on the Vitek MS (regarded as hands-off procedures). 
• Vitek MS - included processing on the Vitek MS until a result was available (regarded as 
hand-off procedure). 
 
The initial capital cost and associated maintenance contracts for all instrumentation were excluded 
from calculations. The crude cost analysis was determined by including direct costs such as reagent 
and consumables (including controls) and excluding indirect costs such as instrument, infrastructure 
and personnel time. Processing of samples for the various methods was done by skilled 
technologists or scientists registered with the Health professions council of South Africa (HPCSA). 
Depending on the complexity of the method or interpretation of the results, the expertise level and 





to perform a crude costing approach as many of the costing values are subject to PathCare’s 
confidentiality agreements (i.e. negotiated costs with suppliers, etc). Ideally concrete values should 
be reported, but we felt that for comparative purposes, reporting cost as a proportion of another 
assay’s cost would be sufficient.  
2.4.1 NTM workflow (hand-on / hands-off) determination 
The current workflow (post-MGIT incubation) in the PathCare TB laboratory is represented in Figure 
2-1. Briefly, ZN stains are performed on positive MGIT cultures after which the MPT64 testing is 
done on all ZN positive MGIT samples. The workflow for MPT64 positive MGIT samples will be 
excluded as it is not applicable to this study. Genotype Mycobacterium CM testing was done on all 
ZN positive, MPT64 negative MGIT cultures and results were reported if a definite identification was 
obtained. If not, the Genotype Mycobacterium AS was performed. If no species was identified, the 
results were reported as Mycobacterium spp. Genotype Mycobacterium CM / AS testing was 
batched and only done on a Monday, Wednesday and Friday in the laboratory. Unloading of positive 
MGIT cultures were done on a daily basis except over weekends and public holidays, therefore, the 
Vitek MS procedure for the identification of NTMs could easily be incorporated into the daily 
workflow.  
 
The average turnaround time for speciation of an NTM by the PathCare TB laboratory was calculated 
for the applicable dataset of samples tested from the time the positive MGIT tube was unloaded from 
the Bactec MGIT 960 instrument, until the result was entered into the Laboratory Information System 
(LIS). The average turnaround time for reporting results using the Mycobacterium CM and AS assays 
was calculated as 3 days. One outlier was excluded from the calculation (17 days) as the test was 
an after-request. Batching samples for the Genotype CM / AS assays led to a longer turnaround 
time, but a result can be potentially produced within 1 day. 
 
Table 2-3 contains details of the time allocated to hands-on and hands-off procedures for the Vitek 
MS when processing NTM isolates of up to 6 isolates a batch. The total time taken to process six 
isolates was just under 3 hours, with only 46 minutes considered as hands-on procedures. This 
dataset represented data where the target slides had been dried in the BSC. If slides had been left 
on the open bench to dry (as per the manufacturer’s instructions), the total processing time would 










Table 2-3 Workflow of processing Nontuberculous mycobacteria isolates on Vitek Mass Spectrometry 
(hh:mm) for a batch of 1 to 6 isolates 
Procedure 1 2 3 4 5 6 
Hands-on 00:08 00:16 00:24 00:32 00:40 00:48 
Hands-off 01:27 01:33 01:39 01:45 01:52 01:58 
Total 01:35 01:49 02:03 02:18 02:32 02:46 
 
For the Vitek MS, the accuracy of the results obtained was not taken into consideration when 
estimating turnaround times, but rather the generation of a first valid Vitek MS result. Repeat or 
alternative testing would have a negative impact on the turnaround time. Not all samples in this study 
could be repeated due to either insufficient sample volume remaining in the MGIT tube, exceeding 
the required incubation time period, or preference given to routine laboratory diagnostic procedures.  
One of the expected benefits of using the Vitek MS for NTM identification was the reduction in 
turnaround time (5,21), however, in this study, the most successful method (Method 1) involved an 
extended incubation period of up to 31 days which then does not provide a time saving over the 3 
days turnaround time of the Mycobacterium CM/AS assays. Method 4 may therefore be more 
promising, as the incubation time was only 6 days, which still allowed additional biomass 
accumulation. 
2.4.2 NTM cost determination 
The focus of the cost analysis was to determine what the Vitek assay would cost in comparison to 
the Genotype Mycobacterium AS / CM assays for the identification of NTM. As actual cost reporting 
is considered sensitive company information, we will report costing in terms of percentage difference 
to Vitek MS. 
 
The cost analysis was calculated from where the sample was flagged positive on the Bactec MGIT 
960 and did not include the culture costs which is the same irrespective of the procedure used for 
downstream analysis/speciation. 
 
The identification of NTMs for a single sample by Genotypic CM and AS assays was 44.3% and 
92.8% respectively, of the cost of the Vitek MS identification. The average of samples processed in 
a batch for the Vitek MS ranges from 1 to 3 samples per batch. The identification of NTMs for a batch 
of 3 samples by the Genotype CM and AS assays was 23.5% and 49.1% respectively, of the cost of 
the Vitek MS identification. The Genotype Mycobacterium CM / AS assays are usually run in 
combination with Genotype MTBDRplus and MTBDRsl assays which increases the number of 
samples per batch, using some of the same consumables and reagents which ultimately decrease 






There is also large wastage of Vitek MS reagents as the Mycobacterium/Nocardia kit is supplied for 
100 tests and the stability once opened is only 4 weeks. 
 
2.5 Conclusion 
While less experienced staff are required to perform the Vitek MS, the prolonged incubation time to 
optimise biomass doubles the current turnaround time of the Vitek MS method. Although NTM 
identification by the Vitek MS can easily fit into our current workflow, the reagent wastage due to 
large NTM/Nocardia kit size does not suit the prevalence of the organisms in our setting.  In 
conclusion, the poor performance of the Vitek MS for the identification of NTMs in our setting (most 
likely due to instrument issues) as well as the increased turnaround time and cost of NTM 
identification suggest that the Mycobacterium CM/AS assays remain the methods of choice in our 
laboratory setting. The opposite may be true for larger regional laboratories such as the National 
Health Laboratory Service (NHLS) who service a much larger patient population affected by 
mycobacterial disease. Reagent efficiency can therefore be optimised by processing larger sample 





 THE IDENTIFICATION OF NOCARDIA 
3.1 Introduction 
The objective of this chapter was to evaluate the performance of the Vitek MALDI-TOF MS for the 
identification of Nocardia spp. by comparing the results to 16S rRNA sequencing and Multilocus 
Sequence Analysis (MLSA). 
 
3.2 Materials and methods  
3.2.1 Sample selection 
Due to the low prevalence of Nocardia infection in our setting, the NHLS Tygerberg Microbiology 
laboratory assisted in sample collection. A total of eight Nocardia isolates were identified  for 
inclusion in the study during the sampling period (July 2018 to August 2019). The isolates were 
stored on Microbank vials (Pro-lab Diagnostics) at -70°C prior to processing.  
Once ready for processing, one or two of the beads were removed from the vial using a sterile 
nichrome loop and plated onto horse blood agar and incubated aerobically at 35 ± 2°C for 48 hours 
or until sufficient growth was obtained. 
 
3.2.2 16S rRNA sequencing 
Nocardia speciation was done by 16S rRNA Sequencing which targets a 598 base pair (bp) section 
of the 16S rRNA gene. This gene contains hypervariable regions which can be used for bacterial 
species identification. 
a) DNA extraction 
A few colonies (pure growth) were selected from the horse blood agar plates and resuspended in 
500µl phosphate buffered saline. 200 µl of each sample was lysed in 180µl of bacterial lysis buffer 
(Roche, MagNA Pure, Switzerland) containing 20µl of proteinase K on a heating block at 60°C for at 
least 15 minutes, or until fully lysed, after which the proteinase K was deactivated at 100°C for 10 
minutes. The lysate was then extracted on 1 of 2 platforms in our laboratory, including the MagNA 
Pure Compact or eMag (bioMérieux, France) instruments as per the manufacturer’s instructions. 
b) Preparation of master mix 
The reaction mix was prepared by adding the reagents to a labelled 0.6 ml tube. Table 3-1 contains 
the volumes and concentration of the reagents used. Sufficient volume of master mix was prepared 
according to the number of samples and controls (positive control [PC] and no template control 





in the reaction consisted of a previously published forward primer PSL (5’-AGG ATT AGA TAC CCT 
GGT AGT CCA-3’) and reverse primer XB4 (5’-GTG TGT ACA AGG CCC GGG AAC-3’) (84). 
 
Table 3-1 Constituents of the 16S Ribosomal  Ribonucleic acid sequencing master mix 
Reagent  Concentration Volume per reaction (µl) 
KAPA Long Range Buffer  5X 4 
MgCl2  25mM 1.4 
dNTPs  10mM 0.6 
XB4 primer  10 pmol/µl 1 
PSL primer  10 pmol/µl 1 
PCR grade dH20  NA 9.9 
KAPA Long Range 
Enzyme 
 5U/µl 0.1 
 
18 μl of the reaction mix was added to a labelled 0.2 ml thin-walled PCR tube or onto a PCR plate 
for each sample and control. 2 μl of the template DNA and control DNA was added to the 
corresponding sample tubes/wells using a pipette and the tubes/wells were sealed. No additional 
PCR grade dH20 was added to the NTC tube. 
c) Amplification 
The 16S target region was amplified using the ABI ProFlex PCR System. Table 3-2 describes the 
touchdown PCR cycling parameters. 
 
Table 3-2 16S Ribosomal Ribonucleic acid amplification program – ABI ProFlex Polymerase chain reaction 
system 
Temperature Time Cycles 















72°C 2 min 1  
4°C ∞ (Hold)  
d) Detection  
Amplification products were visualised by gel electrophoresis on a 2.2% Flashgel (Lonza, 





(Bioline loading buffer) and carefully pipetted into each well. A 100bp ladder (Abbott, United States) 
was also run on the gel to confirm amplicon size. Any samples with positive amplification were 
prepared for sequencing. A run was deemed valid if the positive control showed an amplification 
product and the NTC was clear. 
e) Sequencing PCR reaction 
Dilution of the PCR products was achieved by adding 80 μl of PCR grade water to each well (17.5 
μl amplicon remaining) after which mixing was done by pipetting. The reagents (per reaction) were 
combined as set out in Table 3-3 in a 96 well plate. Separate reactions were prepared for the forward 
and reverse primers. 
 
        Table 3-3 16S Ribosomal Ribonucleic acid sequencing amplification reagents 
Reagent Volume per reaction (µl) 
PCR grade dH20 13 
Big Dye Terminator v3.1  
(Life Technologies) 
2 
Primer (1.1 pmol/µl) 3 
Diluted PCR product 2 
  
The 96 well plate was sealed and centrifuged briefly to collect the contents at the bottom of the wells. 
The plate was transferred to the ABI 9700 thermal cycler for amplification. Table 3-4 contains details 
of the cycling parameters. 
 
         Table 3-4 Amplification program – ABI ProFlex Polymerase chain reaction system 
Temperature (°C) Time (seconds) Number of cycles 








15 ∞ (Hold)  
 
f) DNA purification by ethanol precipitation 
In a new 96 well plate, 2µl of sodium acetate (NaOAc) buffer solution (3M, pH 5.2) was added to 
10µl of the sequencing product. The plate was centrifuged briefly for 5 seconds at 500 x g to ensure 
the NaOAc/EDTA (sodium acetate/ethylenediaminetetraacetic acid) buffer was properly combined 
with the sequencing reactions. 25 μl of 100.0% ethanol (Merck, United States) was added to each 





for 30 minutes at 2 000 x g and the supernatant was removed by gently inverting the tray onto 
absorbant paper towel. The inverted tray was centrifuged for 10 seconds at 50 – 100 x g to remove 
all remnants of liquid onto the absorbant paper towel. 50 μl of 80.0% ethanol was then added to 
each sequencing reaction and centrifuged for 5 minutes at 2 000 x g. The supernatant was removed 
again by inverting the tray on paper towel and by centrifugation for 10 seconds at 50 – 100 x g. 
g) Automated sequence detection on the AB 3500 Genetic Analyser 
The sequencing reactions were prepared for loading onto the capillary DNA sequencer by adding 
10µl Hi-Di Formamide to each sequencing reaction well. The samples were centrifuged for 10-15 
seconds at 900 x g. The sequencing reactions were denatured in a thermal cycler for 2 minutes at 
95°C. The 96 well plate was sequenced in-house using the ABI 3500 genetic analyser. Resultant 
electrophereograms were analysed using BioEdit software and compared to curated online 16S 
databases (SILVA and / or RDP) for genus and/or species identification 
 (https://www.arb-silva.de/aligner/ and/or http://rdp.cme.msu.edu/seqmatch/seqmatch_intro.jsp). A 
cut-off value of ≥97.0% homology for genus level only and ≥99.0% for species level identification 
were used. 
 
3.2.3 Extraction protocol for MALDI-TOF MS 
Fresh Nocardia cultures were revived twice from Microbank storage vials and were prepared by 
adding one loopful of cultured organism (using a 1µl loop or cytology brush) to 500µl of 70.0% 
ethanol in the supplied bead containing tube. The remainder of processing was done as per section 
2.2.3 from cell disruption on the Vortex 2 Genie. 
3.2.4 Nocardia multi-locus sequencing analysis 
MLSA was performed on 7 of the 8 clinical isolates included in the study according to a previously 
published protocol (43). One isolate was excluded due to repeated failure to amplify all MLSA 
targets. The researchers described a five-locus MLSA (gyrB-16S-secA1-hsp65-rpoB) method, but 
they acknowledged that the method may be too laborious, time-consuming and expensive in a 
routine clinical diagnostic setting. They demonstrated similar results (98.5% correlation) when using 
only 3 of the loci (gyrB-16S-secA1). We therefore performed the three-locus MLSA according to the 
published protocol with the following deviations: samples were extracted on the eMAG instrument 
and we used  OneTaq Hot Start DNA polymerase (New England Biolabs, United States). 
 DNA extraction 
 






Forward and reverse primers (Inqaba Biotechnical Industries) for the three selected targets (16S, 
gyrB and SecA1) were used as previously described (43)(Table 3-5). The additional primers listed 
for the gyrB and SecA were used in one sample where sequencing with the main primers was 
unsuccessful.  
Table 3-5 Polymerase chain reaction primers for Nocardia Multilocus sequence analysis  





























































 Preparation of master mix 
The amplification master mix was prepared by adding the reagents to a labelled 0.6 ml tube. Table 
3-6 contains the volumes and concentration of the reagents used. Sufficient volume of master mix 
was prepared according to the number of samples and controls (NTC) to be tested as well as 1 
additional sample to control for pipetting errors. All reagents were pulse spun prior to making up the 
reagent mix. No positive control was added as all isolates were confirmed Nocardia spp. formerly 
identified by the 16S sequencing method. 
 
Table 3-6 Constituents of the Nocardia Multilocus sequence analysis master mix 
Components Concentration Volume per reaction (µl) 
Standard Reaction Buffer 1X 5 
dNTPs 200µM 0.5 
Forward Primer 0.2µM 0.5 
Reverse primer 0.2µM 0.5 
OneTaq Hot Start DNA Polymerase 1.25 units/50µl 0.125 
Template DNA  5 
Nuclease-free water  13.375 






20 μl of the reaction mix was added to a labelled 0.2 ml thin-walled PCR tube or PCR plate for each 
sample and control. 5 μl of the template DNA was added to the corresponding sample tubes/wells 
using a pipette, and the tubes were sealed. The well plate was spun for 15 seconds at 900 x g. 
 Amplification 
The MLSA target regions were amplified on the ABI ProFlex PCR system as previously described 
(43). Briefly, following an initial denaturation step at 98°C for 30 seconds, the samples underwent 35 
cycles of denaturation for 5 seconds at 98°C, 5 seconds primer annealing at 56°C (16S), 60°C (gyrB) 
or 67°C (SecA1), respectively; and 20 seconds elongation at 72°C. This was followed by a final 
elongation step at 72°C for 1 minute and a hold at 4°C. 
 
Suboptimal results were obtained for gyrB and SecA1. Further optimisation was done by gradient 
PCR to determine the optimum annealing temperature for the PCR reactions. The temperature 
ranges tested (in increments of 1°C), are shown in Table 3-7. The number of cycles was also 
increased from 35 to 45.   
 
Table 3-7 Optimising annealing temperatures for gyrB and secA primer sets 
Annealing temperatures 
Sample no gyrB secA1 
1 54°C 61°C 
2 55°C 62°C 
3 56°C 63°C 
4 57°C 64°C 
5 58°C 65°C 
6 59°C 66°C 
 
 Detection 
Amplification products were visualised by gel electrophoresis as per section 3.2.2 d). A 20ng ladder 
(New England Biolabs, United States,  item # NEB N3231S) was also included on the gel. A run was 
deemed valid if the NTC was clear. 
 
 Sequencing PCR reaction 
Subsequent samples with positive amplification were prepared for sequencing as per section 3.2.2 
using the forward and reverse primers for the 16S, gyrB and secA1 targets. Resultant 





fragments of 462 bp for 16S, 482 bp for gyrB and 445 bp for secA1. The sequence fragments were 
concatenated in the order of gyrB-16S-secA to obtain a sequence of 1389 bp.  
  Evolutionary analysis by Maximum Likelihood method 
The concatenated sequences were used for phylogenetic analysis using MEGA X (v10.0.5)( 
https://www.megasoftware.net/home). Briefly we applied the Maximum-Likelihood algorithm based 
on the General Time Reversible model with 1000 bootstrap replication. The tree with the highest 
likelihood was constructed and a bootstrap value of ≥70.0% was deemed acceptable. Reference 
strains were sourced from Genbank and includes N. asiatica, N. beijingensis, N. abscessus, N. 
cyriacigeorgica, N. brasilensis, N. farcinica, N. asteroides, N. neocaledoniensis, N. otitidiscaviarum 
and N. terpinica.  
3.3 Results and discussion 
3.3.1 16S rRNA Sequencing and Vitek MS 
All 8 Nocardia spp. isolates were extracted twice and tested in duplicate on the Vitek MS (Table 3-8). 
 





Duplicate* Vitek MS Identification 
 N1-a Nocardia spp. 
a-b No identification 
c-d N. neocaledoniensis† 
N1-b Nocardia spp. a-b N. neocaledoniensis 
N2-a Nocardia spp. a-b N. cyriacigeorgica  
N2-b Nocardia spp. a-b N. cyriacigeorgica  
N3-a N. otitidiscaviarum a-b N. otitidiscaviarum 
N3-b N. otitidiscaviarum a-b N. otitidiscaviarum 
N4-a Nocardia spp. a-d No identification 
N4-b Nocardia spp. a-b No identification 
N5-a N. otitidiscaviarum 
a-b Bad spectrum 
c-d N. otitidiscaviarum† 
N5-b N. otitidiscaviarum a-b N. otitidiscaviarum 
N6-a N. cyriacigeorgica 
a-b Bad spectrum 
c-d N. otitidiscaviarum 
N6-b N. cyriacigeorgica a-b N. otitidiscaviarum 
N7-a N. farcinica 
a-b Bad spectrum 
c-d No identification† 
N7-b N. farcinica a-b No identification 
N8-a N. terpenica  a-b No identification 
N8-b N. terpenica  a-b No identification 
  * a-b duplicate spots from initial run; c-d duplicate spots from repeat run 






Five of the 8 isolates tested (5/8, 62.5%) correlated with the Vitek MS to the genus level (N1-N3, N5-
N6). Of these, the Vitek MS was able to identifiy Nocardia neocaledoniensis (N1) and Nocardia 
cyriacigeorgica (N2) to the species level where the 16S rRNA sequencing was only able to confirm 
genus.  
 
Of the 5 isolates speciated by 16S rRNA sequencing,  40% (2/5) correlated with the Vitek MS with 
confidence levels of 99.9% (N3, N5). One isolate (1/5, 20.0%) did not correlate with the Vitek MS on 
species level (N6). According to the manufacturer there is a possibility of cross-identification between 
some of the displayed taxa as well as unclaimed taxa (Table 3-9). N. cyriacigeorgica is not listed. 
However, as we see in Table 3-10, the Vitek MS identification was most likely the correct 
identification for this isolate as it correlated with MLSA. 
 










Of the 8 isolates, 5 (62.5%) isolates were repeated after the initial run due to “no identifications” 
obtained (N1, N4-N7). 60% (3/5) of the “no identifications” were resolved with an identification (N1, 
N5-N6), but the remaining 40% (2/5) samples resulted in “no identifications” (good quality spectrums) 
(N4, N7).The overall no identifiction rate was 37.5% (3/8). A “no identification” (good quality 
spectrum) may be due to the presence of an organism not represented in the reference database. 
However the species identified by 16S rRNA sequencing as well as during the repeated Vitek MS 
run suggest that all of these organisms were represented in the Vitek MS database.  
However, as described for NTMs (section 2.3), we encountered numberous issues with and 
discrepancies between different Vitek MS instruments. It therefore cannot be excluded that the “no 
identifications” obtained were due to the suboptimal performance of the instruments. 
 
The Vitek MS performed more accurately for the identification of Nocardia (62.5%) than for NTMs 
(21.8%, section 2.3). The improved performance of the Nocardia assay could be due to the fact that 
Nocardia is processed from solid cultures where NTM were processed from liquid cultures. The 
biomass available for spectrum acquisition on the system is therefore much more than what is 
Vitek MS Displayed taxa 
Reported by Vitek MS 




Vitek MS Displayed taxa Possibility of Claimed taxa 





available in a liquid culture and may be a contributor to the improved performance from solid cultures 
(1). However, the 62.5% accurate identification obtained for Nocardia is much lower than what was 
claimed by the manufacturer (97.9% total correct genus identification). Where they report incorrect 
identifications (0.8%) and only 1.3% “no identifications”, our values were higher (20.0% and 37.5%, 
respectively). Our study results  were statistically different to the manufacturer’s results for correct  
identifications (P = <0.001, 97.9% [bioMérieux] vs 62.5% [our study]),  “no identifications” (P = 
<0.001, 1.3% [bioMérieux] vs 37.5% [our study]) and the number of incorrect identifications (P = 
<0.001, 0.8% [bioMérieux] vs 20.0% [our study]) obtained. 
 
The results obtained on the Vitek MS for the identification of Nocardia range from 83.0% to 98.0%, 
however, most of these studies aimed to develop and validate a comprehensive spectral database 
and was published by the research and development team of bioMérieux (2,35,85). A multicenter 
study published in 2018 showed 76.0% (236/312) correct identification to species level and an 
additional 14.0% (44/312) to the complex level. 3.0% (10/236) of the Nocardia isolates were 
misidentified and 7.0% (22/236) were not identified. This multicenter study was performed as part of 
the Food and Drug Administration (FDA) trial of the Vitek MS 3.0 system (45). We acknowledge that 
the low number of isolates tested (n=8) in our study may contribute to these inflated values, but as 
discussed above, are of the opinion that suboptimal instrument performance was responsible for the 
poor performance of the assay in our setting.  
 
The main hurdle for the implementation of the MALDI-TOF technology for the identification of 
Nocardia spp. in a clinical laboratory is the difficulty of obtaining Nocardia strains for the validation 
of the instrument prior to patient use. The restricted availability of reference data sets of those 
species not frequently isolated in the clinical laboratory and the absence of or the availability of only 
a small number of isolates of a specific species in the reference database, may be the cause of no 
identification results obtained by MALDI-TOF (86).  
 
3.3.2 MLSA 
MLSA was optimised through gradient PCR (section 3.2.4 d) and the annealing temperature selected 
for the gyrB primer set was 57°C and 65°C for the secA1 primer set. 7 of the 8 samples were 
successfully analysed, see Figure 3-1 as an example of the electrophoresis of the optimised PCR 














Figure 3-1 Electrophoresis of optimised Ribosomal Ribonucleic acid products of secA1 
 
Phylogenetic analysis obtained from the 7 clinical isolates revealed several clusters with bootstrap 
threshold values of > 70.0% (Figure 3-2). MLSA confirmed the identification of all 5 Nocardia spp. 
identified to species level by the Vitek MS (Table 3-10). Two previously unidentified species (by Vitek 
MS) were clustered with N. asiatica which is represented in the Vitek MS KB database. The Vitek 
MS and MLSA results correlated better than either method with the 16S rRNA sequencing method. 
The latter was unable to speciate 3 of the isolates and provided alternative ID’s for 2 of the samples 
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Table 3-10 Comparison of Nocardia identification between 16S rRNA, Vitek MS and MLSA 
Sample 16S rRNA Vitek MS MLSA 
1 Nocardia spp. N. neocaledoniensis N. neocaledoniensis 
2 Nocardia spp. N. cyriacigeorgica N. cyriacigeorgica 
3 N. otidiscaviarum N. otidiscaviarum N. otidiscaviarum 
4 Nocardia spp. No identification N. asiatica 
5 N. otidiscaviarum N. otidiscaviarum N. otidiscaviarum 
6 N. cyriacigeorgica N. otidiscaviarum N. otidiscaviarum 
7 N. farcinica No identification N. asiatica 
 
Results from MLSA confirmed the superior performance of the Vitek MS compared to the 16S rRNA 
sequencing for the identification of Nocardia. Limitations of 16S rRNA sequencing is that often it is 
unable to differentiate between closely related species due to insufficient interspecies 
polymorphisms within the 16S rRNA gene sequences (for Nocardia in particular). Incorrect 
identifications can be obtained due to multiple, although different, copies of the 16S rRNA gene 
present in certain species such as N. nova (87).  
While MLSA provided the most identifications, it is a labour intensive and costly exercise which is 
not feasible as a routine test in our setting. 
 
3.4 General Workflow and Cost analysis 
General workflow and cost  determinations were done as per section 2.4 . 
3.4.1 Nocardia workflow (hand-on / hands-off) determination 
Current workflow for Nocardia identification involves the phenotypic identification of Nocardia spp. 
and subsequent confirmation with 16S rRNA sequencing in the molecular laboratory as described in 
section 3.2.2.  
 
The average turnaround time for speciation of Nocardia by the molecular laboratory was calculated 
for the applicable dataset from culture positive until the result was entered into the Laboratory 
Information System (LIS). The average turnaround time for reporting results using the 16S rRNA 
sequencing was calculated as 5 days.  
 
The actual turnaround time for processing on the Vitek MS could not be calculated as the isolates 
selected for the study were retrieved from Microbank storage at -70°C. Hypothetically, after 





days if send to a reference laboratory. For this dataset processing Nocardia isolates on the Vitek MS 
reduced the turnaround time by 3 to 4 days depending on the availability of a Vitek MS on site. 
For Vitek MS analysis, pure growth of the suspected organism was required and if sufficient biomass 
could not be obtained due to the presence of mixed organisms, the need to subculture the primary 
plates would result in a delay of up to 3 days depending on the organism growth.  
 
This highlights the benefit of the availability of a Vitek MS for the identification of Nocardia isolates 
which reduces the turnaround time in comparison to 16S rRNA sequencing which is usually only 
available in a reference laboratory (1,86). 
 
The workflow on the Vitek MS for Nocardia identification was further examined by calculating the 
amount of time needed for hands-on and hands-off procedures for the method.  
Table 3-11 contains details of the time allocated to hands-on and hands-off procedures for the Vitek 
MS when processing Nocardia isolates. The total time it will take to process six isolates on the Vitek 
MS is approximately four hours, but only 41 minutes is allocated to hands-on procedures. 
 
Table 3-11 Workflow of processing Nocardia isolates on Vitek Mass Spectrometry (hh:mm) for a batch of 1 to 
6 isolates 
Procedure 1 2 3 4 5 6 
Hands-on 00:06 00:13 00:20 00:27 00:34 00:41 
Hands-off 02:58 03:02 03:07 03:11 03:15 03:20 
Total 03:05 03:16 03:27 03:39 03:50 04:01 
 
The isolation frequency of Nocardia spp. was extremely low in our setting and isolates will most likely 
be processed one at a time which will take just over 3 hours to complete, with only 6 minutes hands-
on time. 
3.4.2 Nocardia cost determination 
The focus of the crude cost analysis was to determine the cost of the Vitek MS procedure in 
comparison to the 16S rRNA sequencing assay for the identification of Nocardia isolates. We 
reported costing in terms of percentage difference to the Vitek MS.  
As with NTM cost determination, we excluded any capital, maintenance and staffing costs from the 
calculations, but included reagents and consumable costs. The level of staff required and relative 
hands-on time was discussed.  
 
The identification of Nocardia for a single sample by the Vitek MS was 90.6% of the cost of 16S 





increase the number of samples per batch, using the same consumables and reagents which 
ultimately decrease costs for this assay.  
 
As mentioned in Section 2.4.2, the Vitek MS kit is supplied for 100 tests and the stability once opened 
is only 4 weeks. Although the kit reagents are shared with NTM testing, there will be wastage of 
reagents due to the combined number of test requests for these assays. However, the Vitek MS 
requires less experienced staff than the sequencing assay which positively impacts the cost of the 
Vitek MS assay.  
3.5 Conclusion 
In conclusion, this study demonstrated that the Vitek MS has potential to replace 16S rRNA 
sequencing analysis for speciation of Nocardia. However, given the requirement to purchase a large 
Nocardia/Mycobacterium kit , with a limited shelf life, and the poor performance of the method for 
Mycobacteria, most of the kit would expire before possible use. The cost of the assay would therefore 
become prohibitive due to reagent wastage. Should the issues with the Vitek MS instrument be 
resolved and the suppliers provide smaller kit sizes, we recommend a larger scale study to fully 
evaluate the Vitek MS method for Nocardia identification in comparison to MLSA, which appears to 






 THE IDENTIFICATION OF MOULDS 
4.1 Introduction 
The objective of this chapter was to evaluate the performance of the Vitek MALDI-TOF MS for the 
identification of moulds by comparing the results to traditional phenotypic identification and ITS Pan-
Fungal sequencing methods. 
 
4.2 Materials and methods  
4.2.1 Sample selection 
Moulds are frequently isolated in the clinical microbiology laboratory and we were therefore able to 
include a large selection and a variety of species during the sample collection period (January 2019 
to July 2019). Consecutive sample isolates were included, regardless if previosuly isolated from the 
same patient. 
A total of 156 mould isolates were included in the study. This included 140 clinical isolates with 
confirmed fungal infections by  routine MCS at the PathCare Microbiology Reference Laboratory and 
the NHLS Tygerberg microbiology laboratory.  The average age of the mould growth included in the 
study was between 4 to 5 weeks.  
 
16 proficiency testing samples (NHLS Mycology Mould Survey) from 2017 to 2019 were also 
included in the study. These were stored in the original airtight vials at room temperature and were 
revived when ready to be processed.  
4.2.2 Mycology – culture and microscopy 
All samples were cultured onto Sabouraud Dextrose Agar with chloramphenicol (SDC) and 
Sabouraud Dextrose agar with cycloheximide (SABDRUGS) plates and incubated aerobically at 
25°C – 30°C until sufficient growth was obtained. Reading and interpretation of the fungal culture 
plates was done on a weekly basis according to the PathCare SOP with the assistance of competent 
laboratory technologists. Positive cultures of fungal growth were routinely identified by making a wet 
preparation using the lactophenol cotton blue stain to identify the unique fungal features/structures 
and by consulting Microbiology reference books. The phenotypic characteristics noted included the 
size, colour and texture of the fungal colony, pigmentation and the reverse colour of the colony. 
Where NHLS Mycology Mould Survey samples were cultured, plates were checked for purity prior 







4.2.3 ITS Pan-Fungal sequencing 
a) DNA extraction 
DNA was extracted from selected mould cultures using the MagNA Pure Compact or eMag 
instruments as per manufacturer’s specifications with modified pre-processing as per section 3.2.2 
a). 
b) Preparation of master mix 
The reaction mix containing previously published primers (88) was prepared by adding the reagents 
to a labelled 0.6 ml tube. Table 4-1 contains the volumes and concentrations of reagents used. 
Sufficient volume of master mix was prepared according to the number of samples and controls (PC 
and NTC) to be tested as well as one additional sample to control for pipetting errors.  
 
Table 4-1 Constituents of the Pan-Fungal sequencing master mix 
Reagent Volume per reaction (µl) 
ITS1F primer (10 pmol/µl) 1.25 
ITS2 primer (10 pmol/µl) 1.25 
PCR grade dH20  2.5 
KAPA 2G Robust Taq 10 
 
15 μl of the reaction mix was added to a labelled 0.2 ml thin walled PCR tube or PCR plate for each 
sample and control. 5 μl of the template DNA and control DNA was added to the corresponding 
sample tubes/wells using a pipette and the tubes/wells were sealed. 5 μl of the positive control DNA 
was added to the positive control tube and was sealed. No additional PCR grade dH20 water was 
added to the NTC tube. 
 Amplification 
The ITS target region was amplified on the ABI ProFlex PCR System. Table 4-2 describe the details 
















Table 4-2 Internal transcribed spacer Amplification Program – ABI ProFlex Polymerase chain reaction system 
Temperature Time Cycles 















72°C 2 min 1  
4°C ∞ (Hold)  
 
Detection of amplification products, sequencing PCR reaction, DNA purification and automated 
detection of sequences was done as per section 3.2.2 (c) to (g). 
 
Resultant electrophereograms were analysed using BioEdit software and compared to the curated 
online ISHAM-ITS (http://its.mycologylab.org/BioloMICSSequences.aspx?expandparm=f&file=ALL)   
and UNITE databases (https://unite.ut.ee/analysis.php) for species identification. Cut-off values of 
≥97.0% homology for genus level only and ≥99.0% for species level identification were used. 
4.2.4 Extraction protocol for MALDI-TOF MS 
Numerous extraction protocols have been described for successful fungal protein extraction,  
however, 3 of the studies reviewed used a similar protocol (endorsed by bioMéreiux) that showed 
promise and this was therefore used in this study (60,89,90).  
 
The inactivation step involved adding 900 μL of 70.0% ethanol to the provided 2 ml round bottomed 
tube after which the mould was transferred from the culture plate to the ethanol containing tube using 
a cotton swab dampened with sterile water. The tube was centrifuged (Hermle Microliter Centrifuge 
Z233 M-2) at 10 000 x g for 2 min to create a pellet after which all ethanol was removed from the 
tube. Extraction was achieved by adding 40 μl of 70.0% Formic acid and 40 μl of 100.0% Acetonitrile 
after which the tube was centrifuged for 2 minutes at 10 000 x g. The remainder of the protocol was 










4.3 Study results and discussion 
 
A total of 156 mould isolates were extracted and tested on the Vitek MS for identification. Table 4-3 
contains details of the species isolated and evaluated against phenotypic/EQA identification (n=156) 
and ITS Pan- Fungal sequencing (n=26).  
 
Table 4-3 Results of mould isolates on the Vitek  Mass Spectrometry 
Samples highlighted in blue represent correlation to the laboratory reference method. 
Samples highlighted in green represent samples with “no identification”. 
Samples highlighted grey represents samples where the genus correlates with the reference method but differs 
with speciation 
Samples highlighted in orange represent samples that did not correlate with the laboratory reference method. 






(% Confidence level) 
1 Acremonium spp.2 - a-b A. sclerotigenum 
2† Alternaria spp. - 
a-b Bad spectrum 
c-d A. alternata** 
3 Aspergillus spp. - a-b A. fumigatus 
4 Aspergillus spp. A. flavus. a-b A. flavus/oryzae 
5 Aspergillus spp. Aspergillus spp. 
a-b No identification 
c-d A. fumigatus** 
6 Aspergillus spp. - a-b A. fumigatus 
7 Aspergillus spp. - a-b A. fumigatus 
8 Aspergillus spp. - a-b A. fumigatus 
9 Aspergillus spp. - a-b A. fumigatus 
10 Aspergillus spp. - 
a A. flavus/oryzae** 
b No identification 
11 Aspergillus spp. - a-b A. fumigatus** 
12 Aspergillus spp. - 
a No identification 
b A. niger complex** 
13 A. fumigatus A. fumigatus a-b A. fumigatus 
14 A. fumigatus A. fumigatus a-b A. fumigatus 
15† A. fumigatus - a-b A. fumigatus 
16† A. flavus - a-b A. flavus/oryzae 
17 A. niger - a-b A. niger 
18 Bipolaris spp.1 - 
a Bad spectrum 
b E. rostratum ‡** 
19† Curvularia spp.3 - 
a-c Bad spectrum 
d Curvularia lunata** 
20 E. floccossum E. floccossum a-b E. floccossum 
21 Fusarium spp.  a-b F. solani complex 





b Bad spectrum 
23 Fusarium spp. - a-b F. solani complex 
24 Fusarium spp. - a-b F. solani complex 
25 Fusarium spp. - a-b F. solani complex 
26 Geotrichum spp.4 - 
a G. candidum/klebahnii** 
b No identification 
27 L. corymbifera L. corymbifera a-b L. corymbifera 
28 Mucor spp.4 - a-b M. circinelloides 
29 Mucor spp.4 Mucor circelloides 
a-b 
M. circinelloides (50.0%)** 
F. oxysporum complex (50.0%) 
c-d Bad spectrum 
30 M. canis - a-b M. canis 
31 M. canis - a-b M. canis 
32 M. fulvum M. fulvum 
a No identification 
b M. fulvum** 
33† Scedosporium spp.3 - a-b P. boydii ‡ 
34 Trichophyton spp. T. rubrum 
a No identification 
b T. rubrum** 
35 T. rubrum - 
a 
C. ishiwadae (22.7%) 
T. rubrum (25.7%) 
A. sydowii (25.7%) 
E.  floccossum (25.7%) 
b T. rubrum** 
36 T. rubrum - a-b T. rubrum 
37 T. rubrum - a-b T. rubrum 
38 T. rubrum T. rubrum a-b T. rubrum 
39 T. rubrum - a-b T. rubrum 
40 T. rubrum - a-b T. rubrum 
41 T. rubrum - 
a No identification 
b T. rubrum** 
42 T. rubrum - a-b T. rubrum 
43 T. rubrum - a-b T. rubrum 
44 T. rubrum - a-b T. rubrum 
45 T. rubrum - a-b T. rubrum 
46 T. rubrum - a-b T. rubrum 
47 T. rubrum - 
a T. rubrum** 
b Too many peaks 
48 T. rubrum - a-b T. rubrum 
49 T. rubrum - a-b T. rubrum 
50 T. rubrum - 
a-b Bad spectrum 
c-d T. rubrum** 
51 T. rubrum - a-b T. rubrum 
52 T. rubrum - 
a-b Bad spectrum 
c-d T. rubrum** 





b T violaceum 
c-d T rubrum** 
54 T. rubrum - a-b T. rubrum 
55 T. violaceum - a-b T. violaceum 
56 T. violaceum - a-b T. violaceum 
57 T. violaceum - a-b T. violaceum 
58† T. tonsurans - a-b T. tonsurans 
59 T. tonsurans T. tonsurans a-b T. tonsurans 
60 T. verrucosum T. verrucosum a-b T. verrucosum 
61 Acremonium spp.2 - a-b No identification 
62 Acremonium spp.2 - a-b No identification 
63 Acremonium spp.2 - a-b No identification 
64 Acremonium spp.2 - a-b No identification 
65 Acremonium spp.2 - a-b No identification 
66 Acremonium spp.2 - a-b No identification 
67 Acremonium spp.2 Fusarium spp. a-b No identification 
68 Aspergillus spp. A. versicolor 
a-b No identification 
c Too many peaks 
d Background noise 
69 Aspergillus spp. A. giganteus1 a-d No identification 
70 Aspergillus spp. - a-b No identification 
71† A. clavatus 1 - a-b No identification 
72 Bipolaris spp.1 - a-b No identification 
73 C. bertholletiae1 C. bertholletiae1 a-b No identification 
74 Drechslera spp.1 - a-b No identification 
75 Fusarium spp. - 
a Bad spectrum 
b No identification 
76 Fusarium spp. - a-b No identification 
77 Fusarium spp. - a-b No identification 
78† Gliocladium spp.1 - a-b No identification 
79† Mucor spp.4 - a-b No identification 
80 Penicillium spp. - a-b No identification 
81 Rhizopus spp. - a-b No identification 
82 Rhizopus spp. - 
a No identification 
b Too many peaks 
83 Rhizopus spp.3 Unidentified a-b No identification 
84† S. racemosum1 - a-b No identification 
85 T. rubrum - a-b No identification 
86 T. rubrum - a-b No identification 
87 T. rubrum - a-b No identification 
88 T. rubrum - a-b No identification 
89 T. rubrum - 
a No identification 
b Bad spectrum 
90 T. rubrum - a-b No identification 





b Bad spectrum 
92 T. rubrum - a-b No identification 
93 T. rubrum - 
a-b Bad spectrum 
c-d No identification 
94 T. rubrum - a-d No identification 
95 T. mentagrophytes - a-b No identification 
96 T. mentagrophytes - a-b No identification 
97 T. mentagrophytes - a-b No identification 
98 Aspergillus spp. - a-b Bad spectrum 
99 Aspergillus spp. - a-b Bad spectrum 
100 A. niger - a-b Bad spectrum 
101 Bipolaris spp.1 - a-b Bad spectrum 
102 Bipolaris spp.1 - a-b Bad spectrum 
103 Cladosporium spp.2 - a-b Bad spectrum 
104 F. dimerum F. dimerum a-b Bad spectrum 
105 Geotrichum spp.4 - a-b Bad spectrum 
106 M. canis - a-b Bad spectrum 
107† M. canis - a-d Bad spectrum 
108 Mucor spp.4 - a-b Bad spectrum 
109 T. rubrum - a-b Bad spectrum 
110 T. mentagrophytes - a-b Bad spectrum 
111 T. mentagrophytes - a-b Bad spectrum 
112 T. violaceum - 
a-c Bad spectrum 
d Background noise 
113† A. niger - 
a-b Bad spectrum 
c-d A. terreus complex 
114 T. rubrum - a-b T. interdigitale 
115 T. rubrum - 
a T. interdigitale 
b Bad spectrum 
116 T. rubrum - 
a T. interdigitale 
b No identification 
117 T. rubrum - 
a T violaceum 
b Too many peaks 
118 T. rubrum - 
a T. interdigitale 
b Too many peaks 
119 T. rubrum - a-b T. interdigitale 
120 Trichophyton spp. T. mentagrophytes a-b T. interdigitale 
121 T. mentagrophytes - a-b T. interdigitale 
122 T. mentagrophytes - a-b T. interdigitale 
123 T. mentagrophytes - a-b T. interdigitale 
124 T. mentagrophytes - a-b T. interdigitale 
125 T. mentagrophytes - a-b T. interdigitale 
126 T. mentagrophytes - a-b T. interdigitale 
127 T. mentagrophytes - a-b T. interdigitale 





b T. interdigitale 
129 T. mentagrophytes - a-b T. interdigitale 
130 T. mentagrophytes - 
a, c No identification 
b T. erinacei 
d A. benhamiae 
131 T. mentagrophytes - a-b T. interdigitale 
132 T. mentagrophytes - a-b T. interdigitale 
133 T. mentagrophytes - a-b T. interdigitale 
134 T. mentagrophytes - a-b T. interdigitale 
135 T. mentagrophytes - a-b T. interdigitale 
136 T. mentagrophytes - a-b T. interdigitale 
137 Acremonium spp.2 - a-b P. lilacinum 
138 Acremonium spp.2 - 
a T. violaceum 
b T. rubrum 
139 Acremonium spp.2 - 
a F. oxysporum complex 
b Bad spectrum 
140 Acremonium spp.2 - a-b F. oxysporum complex 
141 Acremonium spp.2 - a-b F. oxysporum complex 
142 Aspergillus spp. - 
a No identification 
b S. apiospermum 
143† Aureobasidium spp.1  a-d A. flavus/oryzae 
144 Curvularia spp.3 C. lunata a-d A. fumigatus 
145 E. floccossum - 
a 
C. albicans (49.8%) 
P. vermiculatum (50.1%) 
b P. vermiculatum (99.9%) 
146† E.  floccosum - 
a-b Bad spectrum 
c-d A. flavus/oryzae 
147 F. oxysporum F. oxysporum 
a-b No identification 
c-d A. fumigatus 
148 M. audouinii M. audouinii a-d A. fumigatus 




150 Penicillium spp. P. crysogenum 
a-b No identification 
c-d A. fumigatus 
151 S. prolificans S. prolificans 
a,c No identification 
b F. solani complex 
d Bad spectrum 
152 Trichoderma spp. T. melanomagnum1 a-d A. fumigatus 
153 T. rubrum - 
a Bad spectrum 
b P. lilacinum 
154 T. rubrum - 
a-b No identification 
c-d A. flavus/oryzae 
155 T. rubrum P. lilacinum 
a P. lilacinum (99.9%) 
b 
F. oxysporum complex (20.4%) 





T. interdigitale (20.9%) 
A. fumigatus (20.6%) 
c-d P. lilacinum (99.9%) 
156 T. verrucosum - a-d A. flavus/oryzae 
 
* a-b duplicate spots from initial run; c-d duplicate spots from repeat run 
**Consensus correlates (best result of a repeat / duplicate spot was considered correct) 
† Proficiency Testing Samples 
‡Teleomorph/synonym identified, correlated to genus level (samples 18 & 33) 
#identification results obtained from ISHAM or UNITE database up to species level.  
- Test not done 
1 Isolates not represented in the Vitek MS KB                                                    
2 Only 1 species in the Vitek MS KB  
3 Represented by 2 species in the Vitek MS KB 
4 Represented by 3 species in the Vitek MS KB 
 
Of the 156 isolates tested, 38.5% (60/156, CI95%: 30.8% - 46.1%) correlated with the Vitek MS 
(samples 1-60). Of the 156 isolates, 65.4% (102/156) of isolates were identified by phenotypic 
identification and/or ITS Pan-Fungal sequencing to the species level, of which 38.2% (39/102) 
correleated with the Vitek MS (samples 4,13-17, 20, 27, 29-32, 34-60).  In addition, the Vitek MS 
was able to identify 21 isolates up to species level where phenotypic and ITS Pan-Fungal 
identification  failed to do so (samples 1-3, 5-12, 18-19, 21-26, 28, 33). A limitation of the study was 
that the reference methods did not identify all organisms to the species level, but only to the genus 
level. Where organisms identified by the reference methods to the genus level correspondedto the 
Vitek MS (bioMérieux, France)  genus level, it was considered a 100.0% correlation regardless of 
additional species identification by the Vitek MS (bioMérieux, France). In this study, the Vitek MS 
(bioMérieux, France) was able to provide more species identifications which highlights the fact that 
fungal MCS is an imperfect gold standard. 
 
Of the 156 isolates, 33.3% (52/156,  CI95%: 25.9% - 40.7%) resulted in a “no identification” with 71.2% 
(37/52) as good quality spectrums and 28.8% (15/52) as bad spectrums, too many peaks or 
background noise (samples 61 -112).  Twelfth (12/156, 7.7%) isolates were not represented in the 
Vitek MS database. Seven (7/12, 58.3%) of these resulted in a “no identification” result (good 
spectrum) which is expected when the organism is not in the database and can be considered a 
possible correlation, although it contributed to the high “no identification” percentage. 28.2% (44/156, 
CI95%: 21.1% - 35.3%) isolates did not correlate with the phenotypic and/or ITS Pan-Fungal sequence 
identification (samples 113-156). 54.5% (24/44, CI95%: 39.8% - 69.3%) of these correlated to genus 
level only with the laboratory reference method (samples 113 – 136). Only 2 of these was not 






All single identifications were reported by the Vitek MS with a high confidence level of >90.0%, except 
for one T. interdigitale (63.6%) but this is still regarded as a high confidence level (>60.0%) for 
species level identification. Split identifications (where the Vitek MS was unable to propose only 1 
result) were obtained for 4 isolates (samples 29, 35, 145, 155). Two of these samples which were 
phenotypically identified (samples 29 & 155) were resolved with ITS Pan-Fungal sequencing as M. 
circinelloides (sample 29) and P. lilacinum (sample 155). 
 
The 38.5% accurate identification obtained is much lower than what was claimed by the 
manufacturer which achieved an 92.7% total correct identification. Where they report incorrect 
identifications (0.9%) and 6.4% “no identifications”, our values were higher (28.2% and 33.3%, 
respectively). Our study results  were statistically different to the manufacturer’s results for correct  
identifications (P = <0.001, 92.7% [bioMérieux] vs 38.5% [our study]), “no identifications” (P = 
<0.001, 6.4% [bioMérieux]vs 33.3% [our study]) and the number of incorrect identifications (P = 
<0.001, 0.9% [bioMérieux] vs 28.2% [our study]) obtained. 
 
Rychert et al. also reported increased accurate identifications to species level (91.0%) and an 
addditional 2.0% at genus level. They achieved  6.0% “no identifications” and 1.0 % incorrect 
identifications. Staff members involved in their study received training after which they were required 
to undergo a competency test prior to processing study samples (90). This highlights the complexity 
of  processing mould isolates for identification by MALDI-TOF MS and the requirement for an 
extensive training protocol and standardisation in performing the assay within in the laboratory. In 
contrast to the study results achieved by bioMérieux and Rychert et al., a study published by 
Mcmullen et al., achieved poorer results. 76.8% of their mould isolates were correctly identified with 
0.9% incorrect identification. In their study 22.3% remained unidentified of which the majority of those 
molds (97.0%) were not represented in the database (60). 
 
In total 26 (26/156) isolates were repeated due to incorrect or “no identification” results (samples 2, 
5, 19, 29, 50, 52-53, 68-69, 93-94, 112-113, 130, 143-144, 146-152, 154-156). Six (6/26, 23.1%) 
samples were resolved on repeat analysis (samples 2, 5, 19, 51, 53, 54). This highlights the issues 
encountered with the reliability and repeatability of the Vitek MS instrument evident in the Nocardia 
processing (section 3.3). 
  
The majority of moulds tested belonged to the dermatophyte group (n=81) which comprised of the 
following genera: Microsporum (n=7), Epidermophyton (n=3) and Trichophyton (71).  
 
Of the 71 Trichophyton spp. tested 27 (27/71, 38.0%, CI95%: 26.7% - 49.3%) correlated with the Vitek 
MS (samples 34-60). 17 (17/71, 23.9%, CI95%: 14.0% - 33.9%) isolates resulted in a “no identification” 





spectrums or background noise (samples 109-112). Twenty-seven (27/71,38.0%, CI95%: 26.7% - 
49.3%) phenotypically identified isolates did not correlate with the Vitek MS (samples 114-136, 153-
156). The Vitek MS reported a split identification on 1 of these isolates (sample 155) and was 
resolved with ITS-Pan-Fungal sequencing which correlated with the Vitek MS. 
 
The high percentage (23.9%) of “no identification” results obtained in the Trichophyton group results 
were mostly due to good quality spectrums (76.5%) of which 76.9% (10/13) were identified as  T. 
rubrum by phenotypic identification (samples 85-94). Phenotypic identification is very subjective and 
requires expertise and it can be hypothesised that the organisms may not be represented in the 
database yet and that the phenotypic identification was incorrect to species level. More likely, the 
high percentage of “no identification” (good spectrum) were due to the suboptimal performance of 
the instrument as encountered with NTM processing (section 2.3). 
 
Twenty-three (23/71, 32.4%, CI95%: 21.5% - 43.3%) Trichophyton isolates did not corelate to species 
level with the Vitek MS (samples 114-136) of which 17 (17/23, 73.9%) were T. mentagrophytes, the 
remaining 6 (6/23, 26.1%) were T. rubrum, see Table 4-4. 
 
Table 4-4 Discordant Trichophyton spp. identified on Vitek Mass Spectrometry (species level) 
Phenotypic identification n Vitek MS identification 
T. mentagrophytes 
16 T. interdigitale 
1 T. erinacei 
T. rubrum 
5 T. interdigitale 
1 T. violaceum 
 
This failure of accurate species identification for the Trichophyton isolates may be due to the 
possibility of cross-identification as indicated by the manufacturer, see Table 4-5.  
 
Table 4-5 Vitek Mass Spectrometry possible cross-identification between Trichophyton displayed taxa 
applicable to this study 
Displayed Taxon 
(Reported by Vitek MS) 





T. rubrum T. violaceum 






Most of the cross-identifications were displayed as T. interdigitale. As per manufacturer, 27 out of 
the 30 (90.0%) Trichophyton mentagrophytes tested by them were cross-identified as T. interdigitale. 
This was also reported by Sanguinetti et al. where the mass spectral profiles of T. mentagrophytes 
and T. interdigitale were almost indistinguishable from each other (59). Strains in the T. 
mentagrophytes complex, of which T. interdigitale is a member of, are difficult to distinguish with the 
traditional identification techniques as they are very closely related (53,59). It cannot therefore be 
excluded that the T. mentagrophytes identified by phenotypic means, was indeed not accurately 
identified. T. violaceum can be cross-identified on the Vitek MS as a T. rubrum as was the case in 
our study for sample 117. In our study 5 T. rubrum isolates (samples 114-116, 118-119) were 
identified as T. interdigitale, and 1 T. mentagrophytes as T. erinacei (sample 130) but this cross- 
identification was not indicated as a possibility by the manufacturer.The cross-identifications in the 
Trichophyton group should not have a direct impact on patient management as the treatment of 
onchomycosis caused by these organisms is independent of the causative agents in respect to 
dermatophyte, yeasts and moulds (91).  
 
The second largest mould group tested was the Aspergillus group which comprised of 24 isolates 
(samples 3-17, 68-71, 98-100, 113, 142). This group of moulds showed a better performance in 
comparison to the dermatophyte group with 15 (15/24, 62.5%, CI95%: 43.1% - 81.9%) isolates that 
correlated with the Vitek MS (samples 3 -17). In addition, the Vitek MS was able to identify 9 isolates 
up to species level where phenotypic identification and/or ITS Pan-Fungal identification failed to do 
so (samples 3, 5-12). Seven (7/24, 29.2%, CI95%: 11.0% - 47.4%) isolates resulted in a “no 
identification” with 4 (4/7, 57.1%) as good quality spectrums (samples 68-71) and 3 (3/7, 42.9%) as 
bad spectrums. (samples 98-100). A. clavatus was not represented in the database but as the Vitek 
MS generated a “no identification” (good spectrum) result which can be viewed as correct. Two (2/24, 
8.3%, CI95%: 0.1% - 19.4%) phenotypically identified isolate (sample 142) did not correlate with the 
Vitek MS result of S. apiospermum.  
 
Of a total of 28.2% (44/156, CI95%: 21.1% - 35.3%) for the whole dataset that did not correlate with 
the Vitek MS, 22.7% (10/44) were identified as a member of the Aspergillus group with A. flavus / 
oryzae and A. fumigatus identified as the main pathogens (samples 143-144, 146-150, 152, 154, 
156). The majority of  Aspergillus identifications that did not correlate with the Vitek MS were 
identified from isolates retrieved from storage either from proficiency testing samples or stored 
Tygerberg NHLS samples. At the time when these samples were plated out for processing on the 
Vitek MS, they were considered pure cultures. These isolates were incubated untill good growth 
were obtained which were between 1 to 2 weeks before analysis which is less than the average of 
4 weeks obtained for clinical samples. There is the possibility that the storage conditions prior to 





of the organisms which were less mature than if grown for 4 weeks . The Vitek MS database has 
been constructed including the different protein profiles of the organisms as incubation time progress 
(90), but as Aspergillus is a known laboratory contaminant, it is more likely the cause of the 
discordant results.According to the manufacturer there is a possibility of cross-identification between 
the Vitek MS displayed taxon and unclaimed taxon. The only one applicable to the Aspergillus group 
was A. nominus (unclaimed taxon) which can be reported as A. flavus / oryzae.  
 
The performance of the assay for the remaining dermatophyte genera (Microsporum and 
Epidermophyton) was also not optimal. 40.0% (4/10) were correctly identified to the genus and 
species level (samples 20, 30-32). Two of the 3 (2/3, 66.7%) E. floccosum and both (2/2, 100%) M. 
audouinii isolates were incorrectly identified by the Vitek MS (145-146, 148-149) and 2 (2/4, 50%) of 
the M. canis isolates could also not be identified due to bad quality spectrums (samples 106-107). 
 
Several factors can influence the protein spectrum of organisms, including agar contamination, 
maturation stage of selected colonies and the presence or absence of conidia or melanin in some 
moulds which may affect ionisation (58). The majority of the previously stored samples (EQA and 
NHLS samples) were sub-cultured again and processed on a specific Vitek MS, which required a 
hardware change during the study (linear detector), however, there was no improvement in the 
results.  
 
Three Acremonium spp. identified phenotypically by PathCare Microbiology department were 
identified as F. oxysporum complex by the Vitek MS. Fusarium spp. is one of the most challenging 
genera to identify via traditional macroscopy and microscopy examinations due to its high phenotypic 
variability and the division between sexual and asexual stage taxonomy. It is commonly identified as 
Acremonium spp. as they do look very similar microscopically, therefore, there is a strong possibility 
that the Acremonium spp. identified by the laboratory was indeed Fusarium spp. which correlated 
with the Vitek MS (https://mycology.adelaide.edu.au/descriptions/hyphomycetes/acremonium/; 
https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/acremonium). 
This hypothesis was strengthened by ITS Pan-Fungal sequencing of one of the phenotypically 
identified Acremoniom spp, which confirmed that the isolate was Fusarium spp (sample 67).  
 
Conidial melanin pigment present in highly pigmented moulds such as A. niger and Fusarium spp. 
inhibit ionisation and could have contributed to the lower identification rates obtained by these 
organisms (58). Five  of the 10 (5/10, 50.0%) Fusarium spp. tested, were identified by the Vitek MS 
to genus level and only 1 of 3 (1/3, 33.3%) A. niger  isolates tested was identified to specie levels 






A major limitation of this study was the suboptimal performance of the instruments as previously 
discussed (section 2.3). Several slides were reshooted on another available Vitek MS in the 
Microbiology department as well as on a Vitek MS in another pathology group to compare results, 
but no improvements were seen. Another major limitation of this study is that not all phenotypic 
identification results could be subjected to ITS Pan-Fungal sequencing due to high cost implications 
and phenotypic identification of moulds is an imperfect reference standard.  
 
For many decades direct microscopy and fungal culture from clinical samples has been the gold 
standard in the identification of fungal species but requires highly skilled and trained staff usually 
only found in reference laboratories (50). Molecular methods (e.g. sequencing) have been used 
successfully but the methods are expensive, require specialised equipment and expert staff and is 
usually only available in reference laboratories (59). The application of MALDI-TOF MS for the 
identification of moulds can result in the loss of skills and expertise to visually identify fungi 
microscopically and macroscopically due to the simplicity of the extraction and identification 
procedure on the Vitek MS (24), although the advantage is that it can be employed in peripheral 
laboratories where there is a lack of expertise.   
4.4 General workflow and cost Analysis 
General workflow and cost determinations were done as per section 2.4. 
4.4.1 Moulds workflow (hand-on / hands-off) determination 
The average turnaround time for identification of moulds by the PathCare Microbiology laboratory by 
routine phenotypic methods was calculated for the applicable dataset from the time the original 
sample was received in the laboratory, until the result was entered into the Laboratory Information 
System (LIS) which was on average 3 weeks and 1 day. The disadvantage of phenotypic and Vitek 
MS identification of moulds is that both require growth on solid media prior to processing, resulting 
in the same turnaround time for the Vitek MS as for phenotypic identification. Good growth of 
approximately 4 weeks is required prior to processing on the Vitek MS. ITS Pan-Fungal sequencing 
can be performed directly from clinical samples and is routinely run in batches twice a week. The 
average turnaround time in our laboratory for ITS Pan-Fungal sequencing from clinical samples is 
therefore 7 days.  
 
The workflow on the Vitek MS for the identification of moulds was further examined by calculating 
the amount of time needed for hands-on and hands-off procedures for the method.  
Table 4-6 contains details of the time allocated to hand-on and hands-off procedures for the Vitek 





isolates is just over 2 hours, but only 20 minutes is allocated to hands-on procedures.  The remaining 
01:46 is time allocated to hands-off procedures. 
 
Table 4-6 Workflow of processing mould isolates on Vitek Mass Spectrometry (hh:mm) for a batch of 1 to 6 
isolates 
Procedure 1 2 3 4 5 6 
Hands-on 00:03 00:06 00:10 00:13 00:17 00:20 
Hands-off 01:29 01:32 01:36 01:39 01:43 01:46 
Total 01:32 01:39 01:46 01:53 02:00 02:07 
 
The timespan to identify a single mould isolate on the Vitek MS was estimated as 1 hours and 32 
minutes of which 3 minutes was allocated to hands-on procedures.  
 
The phenotypic identification by lactophenol cotton blue stain took far less time than the Vitek MS  
for a single mould isolate to generate a result. Although the total timespan of mould identification on 
the Vitek MS is far more to generate a final result, the hand-on procedures might be the same as for 
the phenotypic identification depending on the experience and expertise of the technologist. The 
reporting of the result to the client will not be delayed by days but rather hours if the Vitek MS is 
used.  
 
Smaller laboratories can benefit by implementing MALDI-TOF MS for mould identification as the 
isolates can be processed in-house and not be referred to a reference laboratory which may have a 
positive impact on the turnaround time for mould identification in a peripheral laboratory.  
4.4.2 Moulds cost determination 
The focus of the crude cost analysis is to determine what the Vitek MS assay will cost in comparison 
to ITS Pan-Fungal sequencing assay and traditional phenotypic identification of mould isolates.  
 
We reported costing in terms of percentage difference to the Vitek MS.  
As with NTM cost determination, we excluded any capital, maintenance and staffing costs from the 
calculations, but included reagents and consumable costs. The level of staff required and relative 
hands-on time was discussed.  
 
The identification of a single mould by the Vitek MS is 22.0% of the cost of ITS Pan-Fungal 
sequencing, which is the most expensive method. Phenotypic identification is only 0.3% of the cost 
of sequencing and 1.3% of the Vitek MS identification.   
Cost analysis done by Dr Barker from ARUP laboratories also found that the implementation of 





personnel are employed (74). Although Vitek MS identification is considerably more cost effective 
than ITS Pan-Fungal sequencing the opposite is true when compared to phenotypic identification 
which is the primary identification method used in our setting. In contrast to the NTM and Nocardia 
testing, there were minimal wastage of reagents as sample volume was much higher than the other 
two groups of organisms tested and reagents were used optimally before the reagent open vial 
stability expired.  
 
4.5 Conclusion 
In conclusion, this study demonstrated that the Vitek MS is not a suitable replacement for phenotypic 
identification in our setting due to the high failure rate and higher cost of the method. However, 
should issues with the instrumentation be overcome, there is the potential to revisit implementation 
of the assay should their be a shortage of staff experienced in phenotypic speciation methods. 
Furthermore, ITS Pan-Fungal sequencing is more expensive than the Vitek MS and routine 
microscopy, it may have benefits where a reduced turn around time is essential or where there is 








 GENERAL CONCLUSION 
 
Several studies have been conducted on the use of MALDI-TOF MS for the identification of NTM, 
Nocardia spp. and moulds but the majority of studies concentrated on the Bruker technology and the 
construction of laboratory-developed databases to supplement the commercial database available 
from the manufacturer. These laboratory-developed databases improved the performance of the 
MALDI-TOF assay when used in conjunction with the commercial database available from the 
manufacturer. A disadvantage of this is that these databases are laboratory specific and not available 
to use by other laboratories. This is in contrast to sequence alignment databases for bacteria and 
fungi such as Genbank, ISHAM and SINA.  
 
In our setting, the results obtained for the identification of NTM, Nocardia and moulds on the Vitek 
MS v3.2 KB did not match the performance characteristics claimed by the manufacturer or previously 
published studies. Although certain issues were highlighted during our study which included inferior 
quality spots and incorrect handling of the calibration E.coli strain, we were unable to resolve the 
problem.  The high rate of “no identifications” experienced in our study were not due to organisms 
not being in the database, but due to suspected software and/or hardware issues on an instrument 
which requires regular intervention and fine tuning. A high throughput laboratory requires a number 
of back up systems in the event of instrument problems or failures. We currently have 2 Vitek MS 
instruments, however both delivered suboptimal results.  
We therefore recommend that the Mycobacterium CM/AS assays remain the methods of choice in 
our laboratory setting. The Nocardia identification on the Vitek MS showed potential with a higher 
identification rate but is not cost effective due to the low isolation frequency in our setting. The 
performance of MLSA was superior to 16S rRNA sequencing and this may show potential for 
implementation, but is costly. We therefore suggest investigating an alternative single gene target 
for Nocardia speciation following culture which may be more cost effective. The poor performance 
in our setting for mould identification (most likely due to instrument issues) by the Vitek MS  suggest 
that phenotypic identification remains the most promising speciation technique, with ITS Pan-Fungal 
sequencing as an alternative for culture negative samples, or where turn-around time is critical. 
A major limitation of the study is the continued issues experienced with the Vitek MS instrument and 
continuous trouble-shooting of the “no identification” results. Following testing by the manufacturer, 
we suspect that there is a calibration or software/hardware issue which could not be resolved. We 
are concerned that the fragility of the instrument may be a hinderance to the use of the method in 
our high throughput environment. As the first such study conducted in South Africa, the Vitek MS 
database was challenged with locally circulating strains as opposed to those prevalent in the 
manufacturer’s research and development sites. This may have lead to a the decreased sensitivity 
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Appendix A: Vitek MS Technology 
 
The Vitek MS uses a 5-step identification algorithm to obtain an identification result (92). 
 
Step 1 - Spectra (Acquisition)  
The acquisition station software and sample programming will not be discussed in detail but relevant 
information will be included to demonstrate how results are displayed while acquisition is in progress 
and how to interpret those results from the software screen display. 
 
The software displays four target slides with sample and calibration spots on the screen before slides 
are loaded and scanned for acquisition. Once the slides have been loaded onto the instrument, the 
instrument will prepare itself for the acquisition and display the programmed sample and calibration 







Figure A-1 VITEK Mass Spectrometry acquisition station screen displaying programmed sample spots (93) 
 
The instrument will automatically initiate acquisition once the operating pressure has been reached 
and first starts with the calibration spot in an acquisition group. The calibration needs to pass before 
the first sample spot will be analysed. Once all the sample spots in an acquisition group have been 
analysed, the calibration spot will be tested again as an internal check before proceeding to the 
second acquisition group. 
 
When acquisition is taking place, the instrument will fire the laser onto the inoculated spot on the 
target slide. The instrument will fire on set points on the target slide, which are called raster points. 
The laser will hit each raster point 5 times creating 1 profile. The target is to obtain 100 good profiles, 
but a minimum of 30 good profiles is still acceptable and can result in an identification. Each profile 
must pass specific quality control criteria. If acceptable protein profiles are not obtained during the 
firing of a specific raster point, the instrument will move on to the next raster point until 100 good 
profiles have been obtained or alternatively all raster points have been exhausted. If a spot has failed 
identification (e.g. sample spot bad acquisition) then it implies that either a) all raster points have 
been exhausted, b) there was either not enough peak data or c) when the peak data was analysed 
the criteria for a “good spot” was not met. If the peak criteria are not met, a spot will not pass for 







The software displays the particular spectrum and the number of profiles that passes while it is in 
the process of firing the laser onto the slide (93).  
 
 
Figure A-2 VITEK Mass Spectrometry acquisition station screen (93) 
 
An instrument will determine the average of all the spectra collected for the sample (raw spectrum), 
removing the background noise and smoothing results in an averaged processed spectrum. At this 
stage, peak detection takes place and lists of peaks are created according to the mass and intensity 
of the peaks obtained. Figure A-3 is a schematic presentation of this process which can be viewed 







Figure A-3 Spectra obtained and processed during the acquisition of a sample (94) 
 
There are various spot colours that can be displayed depending on the status of the spot’s acquisition 
as seen in Table A-1 and Figure A-2 (93,94). 
 




Spot Colour Description 
 Grey Spot with no sample. 
 Dark grey Spot acquired during previous acquisition. 
 Dark Blue Spot waiting for acquisition. 




Spot where spectrum has been acquired and passed quality 







Green with red 
border 
Spot where spectrum has been acquired and passed quality 
checks. Not submitted to the Analysis Server/ MYLA® 
(communication error). Submission to the Analysis 
Server/MYLA® will be automatically retried. 
 
Red with green 
border 
Spot where spectrum has been acquired and failed quality 
checks. Resulting spectrum peak list is however submitted 
to the Analysis Server/MYLA® which may or may not 
provide an identification. 
 
Red with red 
border 
Spot where spectrum has been acquired and failed quality 
checks. Not submitted to the Analysis Server/ MYLA® 
(communication error). Submission to the Analysis 
Server/MYLA® will be automatically retried. 
 Light yellow Spot selected for re-acquisition 
 
Step 2 – QC filtering and binning  
Bin matrixing is a methodology that is proprietary to bioMérieux and the Vitek. The simplest way to 
describe this is by looking at two genetically similar organisms: coagulase-negative Staphylococcus 
and S. aureus. The peaks generated by these two organisms are sufficiently similar for the Vitek MS 
to call it a Staphylococcus but small variations that exists between the two species allows for the 
accurate differentiation at species level (83). Bin matrixing involves the instrument evaluating each 
peak of the spectrum to determine if its presence or absence is related to species identification. The 
pre-processed spectrum is divided into 1300 predefined intervals and these are called the “bins”. 
Only the peak with the highest intensity is retained in each bin, and the other peaks are discarded. 
This algorithm transforms the list of peaks of variable intensity into a list of bins with the 
corresponding intensity. Each peak is then weighted based on its specificity at the genus level and 
species level. This reduction in data allows memory gain and a more rapid calculation time, but the 
disadvantage is that it prevents the creation of in-house laboratory developed databases (95). 
 
It is also at this stage that QC filtering is taking place which must pass to enable the deliverance of 







Figure A-4 Binned peak list (bioMérieux) 
 
Step 3 – Score and confidence level computation  
The binned peak list is sent to the MS-ID server, Myla, where the sample binned peak list is 
compared to the selected database classes. The MS-ID server calculates 756 scores and 
probabilities for the bacterial protocol or 157 scores and probabilities for the Fungal protocol. Figure 




Figure A-5 Score and confidence level computation (bioMérieux) 
 
Step 4 – Decision stage  
Zero to 4 classes will be retained dependent on 5 parameters (92): 
• Score thresholds: > -0.4 
• Score tolerance*: ± 0.5 
• Probability thresholds: >60.0% 
• Probability tolerance*: 0.3 / 30.0% 
• Maximum number of low discriminations: 4 






Step 5 – Results in Myla  
Identification results generated by the Vitek MS may fall within one of three categories (93):  
• A single high confidence identification  
• A split identification 
• No identification 
 
The Vitek MS reports a confidence level along with the results. A single high confidence identification 
is one significant organism or organism group identified with a confidence value between 60.0%-
99.9 (%). A split identification will result in low discrimination and happens when no more than four 
organisms are identified as possibilities in which the sum of the confidence levels will be equal to 
100. No identification results may be due to more than four organisms or organism groups being 
identified; a list of possible organisms is displayed and the sum of the confidence values will be less 
than 100 or when no match is found in the database, the organism is also considered as not identified 
(93). 
 
The following symbols are also displayed as seen in Figure A-6: 
• High confidence results  
• Low discrimination results 




Figure A-6 Example of Vitek Mass Spectrometry result screen (93) 
 
 







Table A-2 Possible causes of absent or unexpected identifications (68) 
 
Poor Quality or No Mass Spectrum: No identification obtained 
• Matrix was not added before analysis. 
• Too much or too little biomass was used in analysis. 
• Biomass and/or matrix do not cover the entire target spot. 
• Isolate is mucoid; too much capsular material was transferred to target slide. 
• Organism type is not responsive to the direct colony transfer technique, extraction is needed. 
• Organism biomass is contaminated with agar or primary specimen. 
• Culture is mixed, organism not properly isolated. 
• Reagents have expired / evaporated / crystallised or were incorrectly prepared. 
• Organism is too old or too young. 
• Organism was refrigerated before analysis. 
• Scratches or dents are on the target slide or plate. 
• Laser intensity is inadequate. 
• Detector needs maintenance or replacement. 
• Uneven target spot application. 
Good Quality Mass Spectrum: Unexpected identification, Split identification or No identification 
• The sample was transferred to the wrong spot on the target slide (inaccurate sample tracking) 
• Sample cross-contamination is present (this may occur from sloppy spotting, using a single pipette 
to apply the matrix to multiple spots, or from inadequate cleaning of reusable slides). 
• The culture is mixed (the microorganism not properly isolated before analysis). 
• Reagents are contaminated with microorganisms. 
















Appendix B: List of NTM, Nocardia spp. and moulds included in KB 3.2 (79) 
    
Displayed identification 
NTM 
Mycobacterium abscessus Mycobacterium gordonae 
Mycobacterium agri Mycobacterium haemophilum 
Mycobacterium arupense Mycobacterium immunogenum 
Mycobacterium asiaticum Mycobacterium intracellulare 
Mycobacterium aurum Mycobacterium kansasii 
Mycobacterium avium Mycobacterium kubicae 
Mycobacterium brisbanense Mycobacterium lentiflavum 
Mycobacterium celatum Mycobacterium mageritense 
Mycobacterium chelonae Mycobacterium malmoense 
Mycobacterium cosmeticum Mycobacterium marinum 
Mycobacterium flavescens Mycobacterium mucogenicum 
Mycobacterium fortuitum group Mycobacterium nebraskense 
Mycobacterium alvei Mycobacterium neoaurum 
Mycobacterium farcinogenes Mycobacterium paraffinicum 
Mycobacterium fortuitum Mycobacterium phlei 
Mycobacterium fortuitum ssp fortuitum Mycobacterium scrofulaceum 
Mycobacterium houstonense Mycobacterium shimoidei 
Mycobacterium peregrinum Mycobacterium simiae 
Mycobacterium porcinum Mycobacterium smegmatis 
Mycobacterium senegalense Mycobacterium szulgai 
Mycobacterium gastri Mycobacterium triplex 
Mycobacterium genavense Mycobacterium vaccae 
Mycobacterium goodii Mycobacterium xenopi 
NOCARDIA 
Nocardia abscessus Nocardia neocaledoniensis 
Nocardia africana/nova Nocardia otitidiscaviarum 
Nocardia asiatica Nocardia paucivorans 
Nocardia asteroides Nocardia pseudobrasiliensis 





Nocardia carnea Nocardia veterana 
Nocardia cyriacigeorgica Nocardia wallacei 
Nocardia farcinica  
MOULDS 
Acremonium polychromum Lecythophora hoffmannii 
Acremonium sclerotigenum Lichtheimia corymbifera 
Alternaria alternata Metarhizium anisopliae var anisopliae 
Arthroderma benhamiae Microsporum audouinii 
Aspergillus brasiliensis Microsporum canis 
Aspergillus calidoustus/ustus Microsporum fulvum 
Aspergillus candidus Microsporum gypseum 
Aspergillus flavus/oryzae Microsporum persicolor 
Aspergillus fumigatus Microsporum praecox 
Aspergillus glaucus Mucor circinelloides 
Aspergillus lentulus Mucor circinelloides 
Aspergillus nidulans Mucor circinelloides f.sp circinelloides 
Aspergillus niger complex Mucor lanceolatus 
 Aspergillus niger Mucor racemosus complex 
Aspergillus tubingensis Mucor velutinosus 
Aspergillus ochraceus/westerdijkiae Myrmecridium schulzeri 
Aspergillus sydowii Ochroconis humicola 
Aspergillus tamarii Oxyporus corticola 
Aspergillus terreus complex Paecilomyces fulvus 
Aspergillus thermomutatus Paecilomyces variotii complex 
Aspergillus unguis Paracoccidioides brasiliensis 
Aspergillus versicolor Penicillium brevicompactum 
Aureobasidium pullulans Penicillium brevicompactum 
Beauveria bassiana Penicillium brevicompactum ssp biourgeianum 
Bjerkandera adusta Penicillium camemberti 
Blastomyces dermatitidis Penicillium chrysogenum 
Chaetomium globosum Penicillium citrinum 
Cladophialophora bantiana Penicillium decumbens 
Cladosporium cladosporioides complex Penicillium expansum 





        Bold text: Organisms new in KB v3.2  






Coccidioides immitis/posadasii Penicillium italicum 
Curvularia hawaiiensis Penicillium pinophilum/aculeatum 
Curvularia lunata Penicillium roqueforti 
Curvularia spicifera Penicillium vermiculatum 
Epicoccum nigrum Phialemonium obovatum 
Epidermophyton floccosum Pseudallescheria boydii 
Eutypella scoparia Purpureocillium lilacinum 
Exophiala dermatitidis Rasamsonia argillacea complex 
Exophiala phaeromuriformis complex Rhizopus arrhizus complex 
Exophiala spinifera Rhizopus microsporus complex 
Exophiala xenobiotica Sarocladium kiliense 
Exserohilum rostratum Scedosporium apiospermum 
Fusarium chlamydosporum complex Scedosporium prolificans 
Fusarium dimerum Sporobolomyces salmonicolor 
Fusarium oxysporum complex Trametes lactinea 
Fusarium oxysporum Trametes lactinea 
Fusarium oxysporum f.sp aechmeae Trichoderma ghanense 
Fusarium oxysporum f.sp cyclaminis Trichoderma longibrachiatum 
Fusarium proliferatum Trichophyton equinum 
Fusarium solani complex Trichophyton erinacei 
Fusarium thapsinum Trichophyton interdigitale 
Fusarium tricinctum complex Trichophyton mentagrophytes 
Fusarium verticillioides Trichophyton rubrum 
Geotrichum candidum/klebahnii Trichophyton schoenleinii 
Geotrichum fermentans Trichophyton terrestre 
Histoplasma capsulatum Trichophyton tonsurans 
Irpex lacteus Trichophyton verrucosum 





Appendix C: Maintenance of ATCC 8739 E. coli strain (96) 
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